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Abstract
The aim of vascular tissue engineering (VTE) is to fabricate tissues that are both
mechanically and biologically competent similar to the native vessel they are intended to
replace. To this end, the incorporation of sufficient extracellular matrix elastin and collagen
is important.

The objective of this thesis work was to evaluate the effect of two

biochemical factors, L-ascorbic acid (AA) and all-trans retinoic acid (atRA), on elastin
synthesis when coronary artery smooth muscle cells were cultured on 3D polycaprolactone
(PCL) scaffolds. First, porous PCL scaffolds were fabricated using a solvent casting and
particulate leaching approach. The effect of different solvents (ethyl acetate, chloroform
and tetrahydrofuran) and PCL concentration on the morphology and porosity of the
resulting scaffolds were studied. The best scaffolds (based on SEM and micro-CT analyses)
were fabricated from 30% w/w PCL in ethyl acetate. Second, smooth muscle cells were
cultured on these scaffolds to evaluate elastin synthesis. It was found that concurrent
addition of AA and atRA in both 2-D and 3-D cultures suppressed elastin protein
expression compared with atRA alone. To overcome this effect, sequential biochemical
factors addition was tested. The results demonstrated that sequential but not concurrent
addition of biochemical agents promoted tropoelastin synthesis. This study suggested the
importance of biochemical factor addition strategy to engineer a viable vascular tissue.

Keywords: vascular tissue engineering, vascular smooth muscle cells, elastin, all-trans
retinoic acid, L-ascorbic acid, PCL scaffolds.
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Chapter 1 - Introduction
1.1 Overview
Despite significant progress made in intervention outcomes, cardiovascular disease (CVD)
represents the leading cause of death worldwide. Diseases impacting the small diameter
vasculature, such as the vessels servicing the coronary circulation, are becoming the
leading cause of mortality for all of CVD

[1]

. Alarmingly, these trends are predicted to

increase in the future, likely attributed to an aging population prone to making poor health
decisions. Prophylactic measures to reduce the incidence of CVD have not been effective
due to compliance issues.[2] For replacement of the diseased coronary arteries, autologous
vessels such as the great saphenous vein or internal thoracic artery are the most viable
options yet the likely presence of co-morbidities or removal from previous harvests
indicate that other options are required. While it is possible to utilize allografts or
xenografts, there are significant immune-mediated issues that arise that decrease the
patency of these grafts. As such, there is need for the development of a therapeutically
viable and highly patent small-diameter graft replacement. This can be accomplished
through vascular tissue engineering (VTE) that aims to mimic a native vessel through
synthetic fabrication methods. However, the success of such designs relies on matching the
mechanical properties to that of the native vessels.[3] As collagen and elastin are the two
main proteins that endow the native vessels with their mechanical properties, it is important
to understand their expression in order for enhancement to occur in vitro.
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While collagen can be increased in vitro through L-Ascorbic Acid (AA) addition, a main
challenge of VTE is an inability to understand and promote elastogenesis. Elastin provides
resiliency to the arteries and allows for the accommodation of cyclic loading during the
cardiac cycle. It is thought that elastogenic factors, that aid in stimulating the process,
represent viable avenues to explore. One such factor is all-trans retinoic acid (atRA) that is
a derivative of vitamin A and essential during embryonic development. atRA has been
shown to promote the expression of elastin in 2-D cultures. Additionally, atRA is suggested
to have significant phenotypic control over vascular smooth muscle cells (vSMCs)
whereby a contractile state is produced that is non-proliferative. Thus, atRA appears to be
an ideal candidate for investigation as it can increase elastin while concurrently mitigating
the risk of restenosis usually seen with surgical interventions.[4] That said, few studies have
investigated the combination of AA and atRA on 3-D scaffolds and those that did utilize
long end-points and failed to assess elastogenesis acutely compared to either factor alone.

1.2 Thesis Outline
The thesis contains five chapters that are based on investigations pertaining to the
interaction of hcSMCs with 2-D and 3-D substrates and the fabrication process of 3-D
scaffolds. Chapter 2 introduces the relevant literature of the vasculature anatomy, vascular
disease progression, therapeutic options to treat the pathologies, followed by the need for
vascular tissue engineering and options to augment elastogenesis. The motivation and
objectives of this study are discussed at the end of the chapter. Chapter 3 introduces the
materials and methods and outlines the techniques utilized. Chapter 4 discusses the major

3
findings and results from the work. Chapter 5 comments on the future directions of the
work and potential implications of the findings.
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Chapter 2 – Literature Review
2.1 Vasculature Organization and Function
2.1.1 Circulation Anatomy
Blood vessels are hollow tubes that act as conduits for the cardiac output of the heart,
allowing for systemic tissue perfusion with an oxygenated blood flow while facilitating the
return of deoxygenated blood to the heart. The contraction of the left ventricle of the heart
allows for the distribution of oxygenated blood systemically via the aorta, the initial
segment of the arterial circulation. Distal to the aorta, numerous branches and bifurcations
occur. Each newly created continuous segment is associated with an alternative lumenal
diameter and deviation in the underlying structural detail of the vessel wall which imparts
specific functionality.[5] The aorta transitions to smaller elastic then more muscular arteries
which give rise to numerous arterioles and ultimately the capillaries.[5] The aorta acts as a
Windkessel vessel, attempting to limit pulsatile blood flow in the periphery by dampening
pulse pressure as it possesses relatively higher compliance than other derivatives in the
arterial system.[6] The smaller arteries and the arterioles are more resistive in nature and
thus have a larger impact on the maintenance of mean arterial pressure and control of distal
flow. As the transition to arterioles occurs, there is a slight increase in the mean surface
area of the vessels that reaches a maximum at the capillaries, which have the slowest flow
velocity. Capillaries have the ideal hemodynamic characteristics for gas exchange and
filtration or absorption due to their small wall thickness.[7] The capillaries converge after
gas-exchange occurs at their proximal ends and become venules more distally, the first
structure of the venous circulation. Most venules merge into smaller and then larger veins
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that drain into the inferior or superior vena cava and back into the right atrium of the heart.
Abnormalities in any section of this closed system will compromise downstream tissue
perfusion and thus organ function.

2.1.2 Arterial Circulation: Structural and Histological Detail
The arterial wall is a tri-layered laminar structure consisting of the tunica intima, the tunica
media, and the tunica adventitia.[5] Along the arterial tree, the composition of the arteries
varies and similar, yet variant, stress-strain curves are observed.[8] Numerous studies have
shown that the stress-strain curves will range from elastic to viscoelastic more distally with
a continuum between these points.[5, 8, 9] The proceeding text describes the general features
of an elastic or a more proximal muscular artery to which Figure 2.1 provides an overview
of the arterial wall layers and underlying histological detail in cross-section.

The tunica intima is the innermost layer of the vessel wall that is exposed to the blood flow.
It is composed of a mono-layer lining of endothelial cells (ECs) upon a basement
membrane with a sub-endothelial matrix consisting of loose connective tissue, myointimal
cells, fibroblasts, and extra-cellular constituents. Deep to the tunica intima lies the tunica
media, a muscular layer consisting of circumferentially orientated smooth muscle cells
(SMCs) and interspersed extra-cellular matrix fibers in a lamellar organization. The
junction between the tunica media and overlying tunica intima is delineated by an internal
elastic lamina, which assists in volume accommodation during the cardiac cycle and may
have a role in SMC migration from the medial layer.[10] An external elastic lamina lies
deeper and marks the junction between the overlying tunica media and the tunica
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adventitia. The latter layer is more connective tissue in nature with fibroblasts in addition
to collagenous fibers orientated longitudinally.

Figure 2.1: A. Longitudinal section of an artery indicating the exposed vessel wall layers.
B. Histological cross-section indicating extensive lamellar elastin distribution within the
medial layer.[11] Used with permission from the Publisher.

2.1.3 Arterial Circulation: Extracellular Matrix (ECM) Proteins and Associated
Mechanical Properties
Compared with the highly compliant venous circulation, arteries have significantly higher
elasticity, reversible recoil, and resilience at low strains.[5] These properties allow the
arterial circulation to act as a pressure reservoir, to ensure that blood flows distally
especially during diastole. However, the mechanical properties vary during alternative
loading conditions and relate to the composite nature of arteries facilitating anisotropic
mechanical responses. The classical arterial stress-strain relationship is a non-linear Jshaped curve possessing a low stiffness at low strains while transitioning exponentially to
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a stiffer material at higher strains as shown in Figure 2.2.[5, 12] As such, blood vessels do
not possess simple elastic properties, as non-linearity is observed when distended. These
mechanical characteristics are due to numerous extracellular components produced by the
cells within the vessel layers that collectively comprise the ECM. Specifically, these
mechanical characteristics are due to components mainly within the medial layer,
especially collagen and elastin.[5]

Collagen is a stiff, extracellular protein, possessing a high tensile strength of approximately
1.0×109 N/m2, whose concentration is highest in the tunica adventitia.[13] In the unloaded
condition, collagen assumes a “crimped” state yet when load is applied, additional collagen
fibers will assume a greater proportion of the load-bearing and re-align in the direction of
the applied stress.[14, 15] It was believed that the load-bearing ability of collagen in the
medial layer begins at higher stresses until recently whereby Chow et al. [16] proposed that
medial collagen may be engaged from the onset of strain. Yet, it is the recruitment of
additional load-bearing in parallel with the high tensile strength of collagen that makes the
protein an ideal structural support for protection against aneurysmal development and the
potential for vessel wall rupture, as the artery becomes stiffer as the strain increases.
However, collagen itself does not impart elasticity and it is elastin, an amorphous
constituent within the ECM, that provides this mechanical property.

8

Figure 2.2: Nonlinear mechanical behavior of an artery. A: average circumferential stress
versus stretch ratio. B: circumferential incremental elastic modulus (Einc) versus stretch
ratio. Einc was calculated by determining the local slope of the stress-stretch ratio
relationship in Fig. A. Data shown is for adult mouse aorta.[5] Used with permission from
the Publisher.

Elastin exists within a composite of numerous ECM proteins that collectively are termed
as elastic fibers.[17] Approximately 90% of the elastic fibers have been shown to be derived
from elastin.[18] Intracellularly, elastin is transcribed as a 60-70 kDa tropoelastin precursor
that contains numerous hydrophobic domains.[17] The transcriptional process is
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developmentally regulated, with highest activity during late fetal and early neonatal period
with minimal activity in adulthood due to post-transcriptional mechanisms at the
downstream developmental stages.[19,

20]

Additional segmental regulation occurs during

these periods with the tissue-expression of elastin mainly being restricted to areas that
undergo repetitive stresses.[21] When translated and excreted from the cell, tropoelastin
becomes cross-linked at the cellular membrane by lysyl oxidase and the newly cross-linked
structure is termed as elastin.[17] The aggregation is aided by the numerous hydrophobic
domains which facilitate coacervation of the elastin subunits and promote the formation of
strong desmosine and isodesmosine cross-links that provide the protein with its mechanical
properties.[17,

22]

The aggregates transfer to pre-existing micro-fibrils within the extra-

cellular space, whereby the major component of the micro-fibrils, fibrillin-1, serves as a
scaffold for elastin deposition.[17, 23] The assembling of the composite continues to increase
in size as the elastin coalesces. The assembly process of tropoelastin to elastin and
interaction with the pre-existing micro-fibrils is shown in Figure 2.3.

While elastin possesses a low tensile strength of approximately 4.6×105 N/m2, it functions
best to provide high resilience to the artery with a contributory low stiffness.[13] Chow et
al.[24] have demonstrated that maximal elastin engagement within the medial layer is
reached at approximately 20% strain. Elastin is engaged at these low strains to allow for
slight distensibility of the arterial wall to accommodate increases in blood volume during
the cardiac cycle.
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Figure 2.3: A. Assembly process of elastic fibers beginning at tropoelastin secretion and
association with the cellular membrane where cross-linking occurs by lysyl oxidase. B.
Silver stain (van Gieson) indicating that elastin is most evident within the medial layer of
the vessel wall.[25] Used with permission from the Publisher.

As mentioned earlier, the medial layer contains numerous SMCs in a lamellar organization
interlaced with elastic fibers. The geometry of the tunica media aids in accommodating the
cyclic circumferential strain due to the cardiac cycle. The developing wall stress during
systole is uniformly distributed on the vessel wall due to the residual stress being greater
than zero and studies have suggested that this effect can be mainly attributed to elastin
within the medial layer.[26, 27]At low stresses, the elastic lamellae become more aligned and
taut yet the collagen alignment is more gradual and activated at much higher stresses.
However, during disease states, the underlying structure will be significantly altered.
Various

pathologies,

including

age-induced

degeneration,

atherosclerosis,

and
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hypertension can influence the integrity of the fibers and alternative mechanical properties
will be observed.[15, 28]

2.2 Coronary Arterial Circulation
The coronary arterial circulation is a collection of mainly muscular arteries that begin at
the sinus of Valsalva, where the ascending aorta gives rise to the right and left coronary
arteries (RCA and LCA, respectively) from its right and left sinus openings.[29] The RCA
and LCA will give rise to branches that will supply the entire myocardium. The LCA arises
from the left aortic sinus and gives rise to the left circumflex artery and the anterior
interventricular artery (left anterior descending; LAD). The RCA arises from the right
aortic sinus and progresses laterally along the right side of the heart to give rise to vessels
that mainly supply the right ventricle. In 90% of individuals, the RCA gives rise to the
posterior interventricular artery: termed a right-dominated coronary circulation. Using
arteriograms, Dodge et al.[30] indicated that normal vessel diameters of the LCA, proximal
LAD, and distal LAD are 4.5±0.5 mm, 3.7±0.4 mm, and 1.9±0.4 mm, respectively with
similar values obtained for the RCA and derivatives. The relative sizes between the sexes
appear to vary significantly as documented in numerous studies.[31, 32] That said, the main
deviation between individuals is the alteration in the mechanical properties of the coronary
circulation with age. Specifically, the elastin-collagen ratio decreases with age from 5.43
to 2.57 in the LCA and 3.80 to 1.72 in the RCA.[31] The decrease in the ratio suggests the
progression of stiffer arteries with age. However, ignoring the extremes of age, the typical
mechanical profile of the coronary circulation is as follows: a burst pressure of 2000 mmHg
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[33]

, a maximal circumferential strain reached at 20% distension[34], and a normal pressure

exposure between 50-130 mmHg.[35]

2.3 Coronary Artery Disease (CAD)
Cardiovascular disease (CVD) represents the leading cause of mortality globally from
which coronary artery disease (CAD) is the leading factor.[1, 36] The alarming trend is that
the incidence and prevalence of CVD is increasing. In the United States, it is projected that
approximately 40.5% of the population will be burdened with CVD and the associated
costs are expected to exceed $800 billion by 2030.[37] With advances in healthcare, the
morbidity of the disease and its complications are likely to parallel this trend in augmented
prevalence as individuals live longer lives.

The main instigating factor in the development of CAD is atherosclerosis, a progressive
disease characterized by gradual lumenal narrowing of blood vessels leading to
compromised distal blood flow and tissue perfusion which results in potential ischemic
complications.[38] The pathology increases in prevalence with age due to the progressive
nature of the disease and repeated exposure to mostly modifiable risk factors. A main risk
factor are increased levels of cholesterol and low-density lipoprotein (LDL), whereby the
LDL functions to bring cholesterol and phospholipids to the peripheral cells and tissues
rather than back to the liver for recycling as high-density lipoprotein facilitates.[39]
Normally, LDL circulates within the plasma at low concentrations yet can be elevated due
to a poor diet and diabetes, among other factors.[38, 40] If the endothelium is damaged, which
is likely with hypertension and smoking, then LDL can accumulate within the sub-
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endothelial space within the tunica intima. The resultant response, and the basis of the
pathogenesis of atherosclerosis, is the “response to injury” phenomenon which is an
immune mediated reaction to cope with the lipid insult and endothelial damage.[41] Resident
tissue macrophages within the sub-endothelial layer attempt to phagocytose and remove
the LDL. However, numerous free radicals and potential apoptotic debris are produced
which facilitate the oxidation of LDL within the layer.[38] As the macrophages repetitively
ingest the oxidized LDL, they transition in morphology to become foam cells. The
pathology and lumenal narrowing becomes exacerbated by endothelial damage and the
ability of oxidized LDL to act as a pro-inflammatory and adhesive mediator to circulating
monocytes.[38]

The tunica intima has additional functions pertaining to anti-thrombotic activities under
normal homeostatic conditions. The ECs are able to secrete numerous factors such as nitric
oxide (NO) and prostacyclin (PGI2) which attempt to mitigate adhesion and promote
vasodilation. The initial sign of endothelial damage is a decrease in the levels of NO
produced which consequently leads to lumenal narrowing which facilitates a greater
concentration of circulating clotting and inflammatory factors that can interact with the
endothelium.[42] It is the integrity of the endothelial lining that is paramount as the subendothelial matrix is highly thrombogenic in vivo with collagen and von Willebrand factor
being able to interact with platelets. The damaged endothelium promotes the expression of
specific adhesion molecules that are able to attract leukocytes to the area of damage such
as P-selectin. An inflammatory cascade ensues whereby a fibrous plaque develops that
attempts to cover the area of endothelial damage yet it will encroach and challenge the
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integrity of the arterial lumen.[38] The response impacts the medial SMCs and the
organization of elastin and other ECM proteins as SMC proliferation and protein
production is stimulated. The resultant disorganization of the fibers further augments the
stiffness of the blood vessel.[43] New tropoelastin may be secreted, yet it will not possess
the same arrangement and thus the mechanical properties of the arteries will be
significantly altered, especially as increased collagen is deposited due to the inflammatory
process.

The patency of the coronary arterial circulation is essential to ensure sufficient perfusion
to the myocardium. Coronary artery occlusion follows a gradual course initially
characterized by stable angina which leads to unstable angina and ultimately the potential
for myocardial infarctions. The classification of the varying states is based on the degree
of vessel occlusion. Rarely, blockages occur as a result of an embolus and are usually
associated with atherosclerotic plaques. With higher occlusion percentages, individuals
begin to complain of exertional dyspnea as the decrease in lumenal diameter compromises
myocardial perfusion resulting in the lack of sufficient oxygenation.[44] With progressive
occlusion, a myocardial infarction may occur which is characterized by a massive
compromise in cardiac output and potential conduction disarray which leads to death.

2.4 Therapeutic Interventions for CAD
The initial therapeutic approach should be centered on prophylaxis through lifestyle
modifications and pharmacological therapy. The treatment is based on attempting to reduce
myocardial oxygen demand, which beta-antagonists can provide, or to increase the caliber
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of the coronary vessels and improve exercise tolerance, which is the indication for nitrodilators. Additionally, aspirin or clopidogrel may be recommended to ease the concern of
potential thrombi causing distal ischemia and complications. Unfortunately, the efficacy of
lifestyle modifications and pharmacological therapy suffers from poor patient
compliance.[2] More invasive interventions may be required if these techniques fail.

In the non-surgical setting, the approach is centered on revascularization of occluded
coronary vessels and can be accomplished most commonly with percutaneous coronary
interventions (PCI) which include balloon angioplasty and coronary stenting. PCI entails
the insertion of a wire or catheter, usually into the radial artery, that is guided via imaging
to the site of the coronary occlusion.[45] A meta-analysis comparing the efficacy of PCI
versus conservative pharmacological therapy in chronic stable CAD indicated that PCI fails
to offer any benefit in the management of these patients and may have additional risks.[46]
The main concerns with PCI are the potential for stent restenosis due to increased
disorganized cellular proliferation within and around the stent and the development of
thrombus formation. It has been shown that the main response to the procedure is a
significant increase in intimal thickening.[47] Balloon angioplasty has been shown to have
a 30-60% risk of re-occlusion of the vessel whereas bare metal-stents have an approximate
16-44% risk in the development of restenosis.[48] To reconcile these risks, drug-eluting
stents were developed, however complications can still occur in 3-20% of patients due to
allergic reactions, granulomatous inflammation, and neo-intimal thickening.[49] With the
development of more unstable ischemic inducing states, surgical interventions are
considered as more potent re-vascularization strategies.
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The standard surgical intervention is the coronary artery bypass graft (CABG). The
procedure is based on transferring another vessel to replace the diseased artery. Most
commonly, autografts are used such the great saphenous vein (GSV) or internal thoracic
artery. However, a common occurrence is the presence of co-morbidities that make these
vessels unusable or previous harvests have already removed them. Specifically, the GSV
is usually found to be pathological when harvested, which emphasizes the need for
consideration of other allogenic sources.[50] It is possible to harvest vessels from other
donors or animals, yet significant immune-mediated issues arise due to their inherent
thrombogenicity which has been shown to decrease the patency of the graft within a short
time-frame post-operative in many patients.[51] Unfortunately, those with CAD are likely
to have multi-vessel involvement. A recent meta-analysis comparing PCI to CABG for
those with multi-vessel disease indicated that while CABG resulted in a slightly higher
incidence of strokes, they did reduce the need for future re-vascularization and decreased
long-term mortality.[52] A possible reason for the long-term advantageous use of CABG is
that it may provide a more natural and tailorable environment for the cells to interact with.
However, for small diameter graft replacements, no ideal solution exists as of yet and
synthetic grafts produced in vitro are attempting to address this urgent clinical need.

2.5 Vascular Tissue Engineering (VTE)
2.5.1 Overview
Vascular tissue engineering (VTE) attempts to mimic the native vessel architecture and
fabricate a mechanical analogue of the vessels that will be conducive to cell viability and
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growth potential while maintaining long-term lumenal patency. In blood vessel tissue
engineering, the goal is to fabricate a tissue that is mechanically competent and biologically
responsive in a process that is highly reproducible and consistent. The creation of such an
analogue is termed a tissue engineered blood vessel (TEBV). The classical paradigm of
VTE involves the growth of cells in two-dimensional (2-D) culture and subsequent seeding
onto a three-dimensional (3-D) substrate for maturation. Ideally, maturation will occur in
a bioreactor to mimic the native hemodynamic forces the cells are exposed to in vivo. The
VTE process description for the fabrication of a TEBV is outlined in Figure 2.4.

Figure 2.4: Process description for vascular tissue engineering (VTE). The overall
approach is to harvest cells from patients, expand them in culture and seed them to a 3-D
scaffold for maturation and remodeling in a bioreactor.

2.5.2 Cell Source
The cells utilized for VTE should reflect those found in native vessels, being some
combination of fibroblasts, SMCs, and ECs that populate the three component vessel
layers. ECs provide potent signaling to the underlying SMCs within the vessel which can
direct ECM production and angiogenesis; the latter being highly important given the mass

18
transfer limitations of oxygen when vessel wall thickness is increased.[53] An intact
endothelium significantly reduces the thrombogenicity of the graft at the early implantation
stages – especially if seeded initially with venous ECs which have been shown to be less
thrombogenic than arterial cells.[54,

55]

Additionally, EC capture and seeding can be

enhanced through the utilization of peripheral whole blood (PWB) as it contains numerous
endothelial precursor cells that possess the capacity to differentiate into ECs if the correct
milieu is provided.[56] For instance, the presence of a monolayer lining of ECs was observed
when PWB was added to a decellularized allogenic scaffold.[57] Interestingly, when a graft
is implanted into a patient, ECs have been shown to re-populate the lumenal lining in vivo
with staining confirming the original seeded cells were replaced by native cells within an
acute time-frame.[58] This suggests that vascular grafts may not necessarily need ECs when
implanted given the ability of the ECs to re-populate the graft in vivo. However, if this
were to occur, anti-platelet and anti-coagulative therapy should be provided until
endothelialization occurs for the patient to be at low risk of developing thrombosis.[59]

Given the ability of ECs to re-populate the graft in vivo, the main challenge is how to best
re-populate the graft with the cells that comprise the tunica media and adventitia.[60] Stem
cells have emerged as a viable option as a cell source due to their potential to differentiate
into SMCs. Bone-marrow mesenchymal stem cells, adipose derived stem cells, and human
umbilical cord derived stem cells have shown the ability to express vascular SMC (vSMC)
protein markers in vitro and mimic SMC-like ECM production.[61,

62]

Specifically,

mesenchymal stem cells are a preferred choice due to their ability to be expanded in culture
and avoid immune-mediated responses while maintaining multi-potency and easy access
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for harvesting.[63] While promising, studies are mixed in regards to the adverse effects in
vivo with the use of mesenchymal stem cells which may limit their use until safety can be
ensured.[64] Additionally, while stem cells can be coaxed into differentiating down a vSMC
pathway, given the complexity of the process, a reasonable concern is the extent of the
differentiation.[65]

As the differentiation process has not been optimized in vitro, the simplest way to ease this
concern would be to utilize primary SMCs and fibroblasts - especially when attempting to
investigate signaling pathways within grafts. However, primary SMC lines have been
shown to have variable responses in culture that relate to the donor source.66 SMCs sourced
from older donors produce less collagen and elastin and have less proliferative capacity
than their juvenile counterparts.[66, 67] Regardless of age, primary SMCs show a limited
capacity for proliferation in vitro, where typically 10-30 population doublings occur prior
to senescenece.[67] While stem cells are more robust, there exists ways to circumvent the
growth retardation of vSMCs seen in 2-D culture. As an example, McFetridge et al.

[68]

demonstrated that bioreactor systems can induce SMCs to maintain their in vivo
phenotypes. It is also possible that the utilization of higher initial seeding densities can
circumvent the need for numerous population doublings to increase ECM production.

2.5.3 Scaffolds
The ideal scaffold is expected to mimic the geometry of the tissue to be fabricated and
provide correct clues to the cells that are conducive to growth and ECM production. The
scaffold should initially allow for suitable attachment and anchorage of the cells followed
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by proliferation without a cytotoxic or inhibitory effect. The ideal scaffold candidate would
therefore be native ECM itself, and this can be made possible through the use of
decellularized scaffolds. The native ECM provides a rich source of proteins such as
fibronectin that cells can interact favorably with the matrix.[69] However, decellularization
procedures usually requires the use of detergents and proteases that may disrupt the normal
architecture of the ECM and dislodge potential signaling and attachment components.[70]
The decellularization procedure generally produces variable mechanical change in the
scaffold, usually generating weaker grafts.[70] Since collagen and elastin are essential for
the mechanical properties of arteries, their use has been investigated as a comparable option
to that of decellularized scaffolds. However, it has been found that collagen itself may be
a poor scaffolding material as it loses mechanical strength and stability upon hydration in
addition to potential immune-mediated reactions and disease-risk when extracted from
animal sources.[71] Recombinant technology is attempting to produce collagen, yet the
process remains to be optimized and is not currently a viable option for VTE use.[70] A
major issue with elastin-based scaffolds are their propensity to calcify in vivo which would
mitigate the suitability of the scaffold as the mechanical properties are altered.[72] Another
approach, which would allow more consistent optimization of the required mechanical
properties, is the development of synthetic scaffolds. These scaffolds, if fine-tuned to
match the required properties of the ECM, possess high viability to be mass-produced and
available as an “off-the-shelf” option for surgical interventions.[73] Viable synthetic
scaffolds include biodegradable polymers, such as polyglycolic acid (PGA),
polycaprolactone (PCL), and derivatives synthesized via copolymerization with polymers,
such as poly (lactic-co-glycolic acid), that aim to optimize degradation kinetics of the graft

21
in vivo.[74] The goal is to match the degradation rate in vivo with suitable ECM production
without jeopardizing the mechanical properties as this occurs.[70]

Equally important to the scaffold material is the fabrication method. Electrospinning has
emerged as a promising option for VTE due its ability to facilitate the fabrication of
nanofibrous matrices that mimic the topography of the ECM. The technique involves
subjecting a polymer solution to a high voltage which is ejected through a capillary in a
dynamic unstable manner at a controlled rate. Once ejected, the electrical force is greater
than surface tension which creates nanofibrous polymer mats.[75] The solvent is evaporated
as random fibers are deposited onto a grounded collecting plate. However, while the fibers
mimic the native ECM in morphology, it is difficult to control the exact orientation of the
fibers and a major limitation with electrospinning is a lack of suitable cell infiltration due
to small pore sizes.[76] Another technique that directly addresses this issue is utilizing
hydrogels as the scaffolding material. Hydrogels are composed of hydrophilic polymer
chains that are cross-linked allowing for the gel to swell when placed in an aqueous
environment without a loss of structure.[77] The gel matrix allows for suitable mass transfer
of nutrients and gases and additionally offers a way to ensure suitable cell encapsulation.[78]
However, a major limitation with hydrogels is their lack of mechanical integrity, especially
when utilizing natural polymers compared to synthetic options.[79] Another fabrication
method is that of solvent casting and particulate leaching (SCPL). The technique involves
dissolving a polymer in a suitable solvent and forcing the developing viscous solution
through a porogen bed to which the porogen is leached out in a solvent that does not
dissolve the polymer. The resulting construct will have a porous structure with high overall
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porosity at the macro and micro porous levels. However, SCPL offers limited control over
the orientation of the pores and the overall pore interconnectivity.[80] That said, the benefit
of SCPL is that there is a high control over overall porosity and thus cell infiltration.
Overall, SCPL offers a simple fabrication process with high tunability in a fabrication
method that is cost-effective.[81]

2.5.4 Bioreactors
The use of bioreactors allows for simulation of the native hemodynamic forces. Forces
such as shear stress on the ECs and the pulsatile nature of the blood flow can induce
signaling events. Specifically, these forces have been shown to induce growth and
maturation of the cells significantly different than that of static culture.[82] The stimulation
induces the SMCs to secrete more ECM proteins and has been associated with improved
graft mechanical properties.[83] Mechanical stimulation additionally allows vSMCs to
adopt phenotypes more akin to the in vivo environment which may further explain the
reasoning to these grafts developing higher mechanical properties and improved patency
when cultured within a bioreactor.[84, 85]

2.6 Small-Diameter VTE: Challenges and Potential Solutions
Synthetic grafts made from expanded polytetrafluoroethylene (ePTFE) and polyethylene
terephthalate (PET, Dacron) work well for large diameter vascular graft replacements
(>6 mm diameter) where the blood flow rate is high but results in small diameter coronary
artery graft applications (<4 mm diameter) have been disappointing.[86-88] The main
limitation with small diameter grafts is thrombosis which occludes the lumen and
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exacerbates the pathologies the graft attempts to alleviate. A non-autologous vascular
replacement will induce an immune response, yet the reaction may not necessarily be acute.
Furthermore, if the mechanical properties of the graft are not matched with that of the
native vasculature at the anastomotic sites, the generated turbulent flow induces an
immune-mediated response that can result in lumenal occlusion.[89] These limitations
prompted the field of VTE. Despite rapid advances made in this field, success has been
limited due to significant knowledge gaps in our ability to control and coordinate cell
phenotype and direct tissue formation, which is the ultimate goal for VTE.[90] Particularly,
stimulating and understanding elastogenesis in VTE has been proven to be difficult.[3, 11, 91]
It is understood that for a TEBV to be successful, it must incorporate elastin into the
developing tissue construct to achieve the required overall viscoelasticity of the final
tissue.[11, 92] It is possible that utilizing elastomeric scaffolds could be helpful for improving
the elasticity of the engineered tissue. Indeed, the use of elastomeric scaffolds has resulted
in more akin mechanical properties to that of the native arteries.[93, 94] There is optimism
that a cell-free tissue engineering approach can be based on the use of such scaffolds.[95]
Unfortunately, the approach relies on in vivo re-modeling and it can be expected that the
results will be variable. Additionally, this technique relies on infiltration of native cells and
an immune response to acquire the required remodeling. Yet again, this may vary from
host to host and might not be suitable for the small diameter vasculature.[96] As such, while
the synthesis of elastomeric scaffolds improves the mechanical properties, there is a need
to seed cells prior to implantation. Ideally primary human coronary SMCs (hcSMCs) that
are responsible for producing elastin and assembling it to elastic fibers within the medial
layer would be utilized. If elastin can be produced at high levels and assembled into fibers,
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then the mechanical properties of TEBVs can be expected to increase. An avenue that can
be taken is the use of factors that can stimulate elastogenesis. However, in addition to their
impact on elastogenesis, these factors may influence the phenotype of the vSMCs.

2.7 Vascular Smooth Muscle Cell (vSMC) Culture
2.7.1 vSMC Phenotype
vSMCs represent a dynamic cell line in which their phenotype is not terminally
differentiated and rather exists as a continuum of states between synthetic and
contractile.[97] During development, vSMCs begin in a highly proliferative synthetic state
where ECM protein production is high. A transition occurs that decreases ECM production
and increases intercellular myofilaments, a switch that facilitates the required contractility
within blood vessel walls.[98] Studies have indicated that the transition can be bidirectional.[99, 100] The phenotypic plasticity can vary along the arterial tree during normal
homeostatic conditions due to the presence of alternative populations of vSMCs.[101]
However, in vivo, the phenotypic plasticity is correlated with pathological events such as
seen in atherosclerosis whereby the usual contractile vSMCs in the medial layer can
migrate to the intima and become synthetic, promoting intimal thickening and hyperplasia
– an undesirable outcome. The continuum between synthetic and contractile is classically
characterized by the presence or absence of specific proteins.[97] The contractile state
contains minimal rough endoplasmic reticulum and ribosomes indicating that its function
is not related to extensive ECM protein synthesis.[101] When the vSMCs are in the
contractile state, they have a large volume fraction of myofilaments within their
cytoplasm.[98] The contractile proteome of these cells indicate high expression of
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contractile protein markers such as smooth muscle alpha actin (α-SMA), calponin, SM22α, and smoothelin.[101] De-differentiation into the synthetic phenotype is associated with
a loss of these markers.[101] In addition to quantitative changes in the contractile protein
markers, the modulation in phenotype is also associated with alternative rearrangements
and realignments of the myofilaments.[102] Due to the lower level of protein secretion, the
contractile vSMCs are denser and more fusiform in nature, a stark contrast to the expansive,
broad, and fibroblast-like epithelioid morphology of the synthetic phenotype. When cells
de-differentiate into a synthetic phenotype, a loss of the high volume of myofilaments, a
disappearance (or reduction) of the contractile markers, and an increase in apparatuses
promoting protein production have been observed. Specifically, elastin production is likely
correlated with the synthetic vSMCs phenotype, yet there has been mixed results.[103, 104]
In contrast to the contractile upregulation of vSMC protein specific markers, it is thought
that the synthetic phenotype is characterized by a disappearance of the contractile markers.
However, proteins such as L-caldesmon and meta-vinculin can be used to denote the
synthetic state, yet marker specificity for the synthetic phenotype is not as specific as the
contractile state.[105]

2.7.2 vSMC Response to Microenvironments: 2-D vs. 3-D Culture
Classically, most cell culture investigations have been performed on a 2-D surface yet this
is an inaccurate representation of the in vivo environment. While 2-D culture is a quick and
well-established culture system, it only provides a simplistic and limited substrate that cells
can interact with. Within the ECM, cells are constantly exposed to varying topologies,
gradients, and forces – all of which are difficult, if not impossible, to replicate in a 2-D
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setting. It can be expected that cells will respond and behave differently when seeded in 2D and 3-D environments. When cultured in 2-D, most vSMCs are known to adopt a more
synthetic phenotype compared to a contractile state usually seen in vivo.[101, 106] Yet, most
early experimental designs considered vSMCs only in a 2-D environment, one that is stiffer
than the native ECM found in blood vessels. Indeed, a major difference between 2-D and
3-D is the stiffness of the underlying substrate. Recently, Timraz et al. [107] demonstrated
that collagen-I gels with varying degrees of stiffness can influence vSMC phenotypic
differentiation and protein secretion with the synthetic phenotype being inversely
proportional to increasing the stiffness of the gels. However, the study investigated cellular
responses when encapsulated in a collagen gel and when combined with various ECM
proteins, such as fibronectin, which may influence the manner in which the cells interact
and spread within the matrix as the supplemented factor concentration is increased. The
exact experimental design for investigating how cells respond to variant stiffness in 3-D
remains to be optimized. This may be due to designs that increase the cross-linking density,
consequently increasing the propensity for cell-mediated proteolysis and subsequent
migration.[108] A commonality between how the cells sense stiffness in 2-D and 3-D is
through RhoA, a small GTPase that facilitates mechanotransduction. RhoA activation has
been shown to be upregulated in 2-D culture and in atherosclerosis.[109] When RhoA is
constitutively expressed in vSMCs in 3-D cultures, the state of vSMC differentiation has
been shown to depend on the stiffness of the substrate and produced similar cytoskeletal
effects seen in 2-D culture.[106] Upregulation of RhoA in vSMCs is associated with an
increase in contractile SMC markers in 3-D.[106] While stiffness may have an effect on the
phenotype, the 3-D environment additionally changes the mechanism in which the cells are
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able to sense their surroundings. Using varying matrices, Hong et al.[110] demonstrated
varying temporal differences in ECM expression in 3-D relative to 2-D with significant
variability when alternative 3-D scaffolds were used. Work by Lin et al.

[111]

also

demonstrated that hcSMCs seeded in 3-D expressed higher levels of elastin than in 2-D
culture. However, when TGF-β1 was utilized to increase elastin, the up-regulated
elastogenic effect was noticed only in 3-D and not in 2-D suggesting that the effect of TGFβ1 in 2-D cultures may not translate to 3-D. Another biochemical factor that is elastogenic
but not widely studied is retinoic acid which is a vitamin A derivative. Since this thesis
focuses on retinoic acid, an expanded review is presented in the proceeding section.

2.8 Retinoids
2.8.1 Overview
Retinoids are derivatives of vitamin A that are highly active during embryogenic
development and have been shown to have a positive impact on elastogenesis. Four of the
biologically active derivatives are retinol, retinal, 9-cis retinoic acid (9cRA), and all-trans
retinoic acid (atRA).[112] While there are numerous metabolites, it is atRA which is the
carboxylic acid form that has been shown to have the most potent biological activity.[113] It
should be noted that there have been reports indicating isomerization potential between
atRA and 9cRA intracellularly.[113] As a lipophilic molecule, the atRA concentrations
within the plasma are low - ranging between 1-10 nmol/L.[113] Most in vitro experiments
with atRA utilize the relevant therapeutic and physiological concentration, corresponding
approximately to 1 μmol/L.[113] Due to its lipophilicity, a retinol binding protein (RBP)
associates with atRA within the plasma and carries the molecule to target organs.[114] The
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atRA is able to diffuse past the cellular membrane and an interaction can occur with a
cellular retinoic acid binding protein (CRABP). There are two isoforms of CRABP, being
I/II, though only CRABP-I has been shown to be relevant in vSMCs.[115] Binding to the
CRABPs occur with high affinity and seems to increase the ability of atRA to be
translocated to the nucleus.[116] Within the nucleus, the complex interacts with two subsets
of nuclear receptors being the retinoic acid receptor (RAR) and retinoid X receptor
(RXR)[113], to which there are 3 isoforms of each (α, β, and γ).[117, 118] Both receptors
associate as a heterodimer that are bound to a retinoic acid response element (RARE) near
specific target genes that normally act to repress transcription. Retinoids are able to bind
to the RAR allowing for conformational changes to be induced that create positive
transcriptional effects. Both 9cRA and atRA are able to bind to the RAR yet only 9cRA
can associate directly with the RXR. However, the RXR itself has not been proven to have
physiological relevance. An overview of the metabolism and subsequent processing of
atRA is shown in Figure 2.5.

Figure 2.5: Intracellular effects of atRA. After being transported through the plasma by a
protein carrier, albumin, atRA translocates across the membrane and associates with the
CRABPs that allow nuclear translocation and subsequent transcriptional effects.[113] Used
with permission from the Publisher.
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2.8.2 atRA Impact on vSMC Phenotype
The current understanding of the effect of atRA on vSMC phenotype is that an antiproliferative and differentiated state is induced. Interestingly, atRA is being investigated
for its role is preventing intimal thickening and restenosis following PCI.[4] The elevated
levels of contractile makers have been associated with atRA possessing potential negative
effects on growth and cellular proliferation in human tissue culture. Axel et al.[119] found
that in a dose-dependent manner, atRA decreases both proliferation and migration. The
ability to produce the latter effects may be attributed to a retinoid-inducible tissue transglutaminase (ttG).[120] Recently, in vivo experiments confirm that atRA can inhibit vSMC
proliferation and promote contractile marker expression via upregulation of Kruppel-like
Factor 4 (KLF4), a zinc-finger transcription factor.[121] KLF4 activation has been shown
to activate p53 to inhibit vSMC proliferation.[122] Knockdown studies of KLF4 mitigated
the atRA mediated increase in contractile protein markers being α-SMA and SM-22α.[123]
In rat vSMCs, atRA has been shown to increase the levels of contractile markers such as
α-SMA.[124] The increase in these markers was associated with a stimulation in protein
kinase C-α activity.[124] However, it is not intracellular interference alone that atRA exerts
its anti-proliferative effect, as it has been shown to influence ECM production. Perlecan
sulfate is a large proteoglycan within the ECM that has been shown to have antiproliferative properties. When transgenic mice were engineered to be deficient in perlecan
sulfate expression, the atRA mediated anti-proliferative effect was depressed.[125] That
said, most of the above studies occurred in 2-D culture. The phenotype adopted by vSMCs
in response to atRA treatment may be dependent on the initial state of the cells.[126] The
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different responses obtained in early investigations may be due to the source of vSMCs
and the experimental design.

2.8.3 atRA Impact on Elastin Expression
The effects of atRA seems to be tissue-dependent with pleiotropic impact.[113] In terms of
elastogenesis, atRA has been shown to have potent impact on the pulmonary and arterial
circulations and is associated with dermal elasticity.[127-129] The earliest studies suggesting
atRA may increase elastin occurred in pulmonary lung fibroblasts based on observations
that elastogenesis within the alveolar septa correlated with atRA levels during brief periods
in postnatal life.[130] For the pulmonary circulation, elastin is essential for lung compliance
and proper breathing mechanics. Indeed, deletions in RARs, specifically RARγ, have
corresponded to reduced elastin and alveolar numbers.[131] Similar pathological
manifestations occur within the vasculature when atRA signaling pathways are interfered
with. Pathologies that result from low retinoid levels include an increased mortality from
CAD.[132] Within the arterial tree, the derivatives of vitamin A with the greatest elastogenic
impact are 9cRA and atRA.[133] In aortic SMCs harvested from 18-day old chick embryos
and cultured on 2-D surfaces supplemented with atRA, elastin synthesis increased in a
dose-dependent manner while cell number was decreased compared to the control.[133] This
suggests that if atRA is to be used in VTE, higher cellular seeding densities should be
utilized.

31
2.8.4 atRA in Combination with Ascorbic Acid: Impact on Elastin
Ascorbic Acid (AA) is added to cell culture experiments due to its potent effect on collagen
synthesis in numerous cell types.[134-136] However, supplementation with AA in 2-D culture
attenuates elastogenesis in a concentration dependent manner. AA can influence
elastogenesis at both the transcriptional and post-transcriptional stages by reducing total
transcript number and tropoelastin mRNA stability.[137] There may be an interplay between
the two factors on elastogenesis in long-term cultures. While AA can increase the
mechanical properties of the engineered tissue, the resulting increase in stiffness due to a
lack of elastogenic stimulation may result in a vessel that does not mimic the in vivo
scenario.[138] While atRA was added to mitigate the loss of elasticity, the combination of
both seemed to have a complex impact on elastogenesis.

2.9 Study Rationale and Objectives
Within the VTE field, a major limitation is the inability to properly recapitulate the
mechanical properties of a native tissue. Specifically, in vitro elastogenesis has proven to
be difficult while collagen production can be sufficiently stimulated. It is necessary to
increase both collagen and elastin synthesis to ensure the engineered vessel has suitable
mechanical properties. As the goal would be to increase elastin expression, biochemical
factors can aid in stimulating elastogenesis. Specifically, we suspect that atRA can increase
elastin expression in 3-D cultures. However, as there is a need to promote collagen
synthesis too, AA and atRA may have significant effects on the phenotype of vSMCs that
could be relevant to elastogenesis. In doing so, better understanding of the interaction
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between AA and atRA may lead to the engineering of functional vascular substitutes. In
view of the above, the objectives of this study were to:
i)

Fabricate and characterize PCL scaffolds with suitable porosity conducive to
cellular infiltration and proliferation and

ii)

Evaluate elastogenesis when hcSMCs are seeded on PCL scaffolds and treated with
AA and atRA individually or in combination
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Chapter 3 – Materials and Methods
3.1 Materials
ε-Polycaprolactone (PCL; Mn=80,000 Da) was used to fabricate the 3-D scaffolds and was
obtained from Sigma Aldrich (Oakville, ON, Canada). All solvents used to dissolve the
PCL pellets were obtained from Caledon Labs (Georgetown, ON, Canada) and included
chloroform (CHCl3), ethyl acetate (EtOAc), and tetrahydrofuran (THF). Ammonium
chloride (NH4Cl) was supplied by Caledon Labs and was utilized as the porogen for the 3D scaffolds. Cell culture experiments were conducted on primary hcSMCs in Medium 231
supplied by Life Technologies (Burlington, ON, Canada) and on immortalized NIH-3T3
fibroblasts in DMEM obtained from Lonza Walkersville Inc. (Walkersville, MD, USA).
Medium 231 was supplemented with 5% penicillin G and streptomycin sulfate (P/S),
insulin-like growth factor (IGF), and basic fibroblast growth factor (bFGF). DMEM was
supplemented with 10% fetal bovine serum (FBS) and 5% P/S. All components added were
obtained from Life Technologies. Cellular washing steps were conducted in Hank’s
Balanced Salt Solution (HBSS) supplied by Life Technologies. L-ascorbic acid (AA) and
all-trans retinoic acid (atRA) were obtained from Sigma Aldrich. For cell fixation and
immuno-histochemistry, a 4% paraformaldehyde solution in diH2O was prepared from
paraformaldehyde

obtained

from

EMD

Chemicals

(Gibbstown,

NJ,

USA).

Immunostaining utilized Alexa Fluor® 488 Phalloidin and DAPI (4’,6-diamidino-2phenylindole) supplied by Life Technologies. Mounting medium was obtained from
Vector Laboratories (Burlington, ON, Canada). For qPCR, initial RNA isolation occurred
utilizing Trizol® Reagent supplied by Life Technologies. Glycogen and iQ™ SYBR®
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Green Supermix, used in the RNA purification and cDNA synthesis respectively, were
obtained from Bio-Rad (Mississauga, ON, Canada). RNA work utilized a NanoDrop Lite
Spectrophotometer obtained from Thermo Scientific and a C1000 Touch™ thermal cycler
(CFX96™ Real-time system) supplied by Bio-Rad. Protein quantification for western
blotting was based on the construction of a standard curve utilizing bovine serum albumin
(BSA) supplied by Sigma Aldrich. Protein quantification was completed using the 660 nm
protein assay supplied by Thermo Scientific (Ottawa, ON, Canada). For western blotting,
monoclonal (α-SMA and GAPDH) primary antibodies were obtained from Santa Cruz
Biotechnology (Dallas, TX, USA) and EMD Millipore (Temecula, CA, USA) respectively.
Polyclonal primary antibody against elastin was supplied by EPC (Owens, MO, USA).
Secondary anti-rabbit and anti-goat HRP-conjugated antibodies were supplied by Santa
Cruz Biotechnology. SuperSignal® West Pico Chemiluminescent Substrate was supplied
by Thermo Scientific (Rockford, IL, USA). ChemiDoc™ XRS+ and ImageLab™ software,
obtained from Bio-Rad, were utilized to image and quantify the membranes respectively.

3.2 Methods
3.2.1 Scaffold Fabrication via Solvent Casting and Particulate Leaching (SCPL)
Tubular PCL scaffolds were fabricated using a solvent casting and particulate leaching
(SCPL) method based on previous established protocols in our laboratory.[139] Briefly,
NH4Cl particles were mechanically processed using a mortar and pestle prior to passing
through graded sieves to obtain porogen particle sizes between 180-210 μm. The collected
particles on the 180 μm sieve were re-sieved once, to ensure they fell within the desired
range. PCL pellets were dissolved in various solvents (CHCl3, EtOAc, THF) at 40 ⁰C and
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varying concentrations, ranging from 10-30% w/w. To prepare the porogen bed, the NH4Cl
particles were packed into the annulus of a glass tube with a central mandrel. The polymer
solutions were then infiltrated over the porogen bed using a pressure differential created
by applying vacuum to the inferior aspect of the porogen bed. The glass rod was then
removed from the apparatus and left upright in a fume hood for 2 hours prior to removal
of the scaffolds from the glass rod. The scaffolds were kept for approximately 12 hours, to
dry and allow for solvent evaporation, in the fume hood prior to placement into diH2O. The
tubular scaffolds were cut into small rings cut using a microtome. Rod-like porous
scaffolds were also fabricated by removing the mandrel during the porogen packing. The
SCPL apparatus is shown in Figure 3.1.

Figure 3.1: Solvent casting and particulate leaching apparatus. The digital images shown
are the tubular scaffolds fabricated using the apparatus.
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3.2.2 Scaffold Characterization
3.2.2.1 Scanning Electron Microscopy (SEM)
A scanning electron microscope (2-2600N, Hitachi, Japan) was utilized to assess the
fabricated scaffold morphology. The scaffolds were sectioned into pieces of varying
lengths to investigate the lumenal, ablumenal, and cross-sectional morphologies. The
scaffolds were cut using a microtome and affixed via carbon tape to studs prior to gold
sputtering and subsequent imaging.

3.2.2.2 Microcomputed Tomography (micro-CT)
Scaffolds were sectioned with a microtome into slices 4 mm in length. Imaging occurred
using the eXplore Locus SP (GE Healthcare, Canada). Two different batches of scaffolds
were scanned at a voxel resolution of 11 μm, using an integration time of 1700 ms per
frame with 15 views per frame over 900 views encompassing 360⁰. The x-ray tube voltage
and current were set at 80 kVp and 90 μA respectively. The 2-D images obtained were
compiled to generate 3-D representations of the scaffold architecture. A commercially
available trabecular bone analysis software (MicroView version Viz+2.0, GE HealthCare)
was utilized to analyze the 3-D images. Data analysis considered overall porosity, pore
size, surface area to volume ratio, and strut thickness.

3.2.3 Cell Culture Conditions
Primary hcSMCs, between passage 4-8, were cultured in Medium 231 supplemented with
bFGF, IGF, and 5% P/S. NIH-3T3 fibroblasts, between passages 6-15, were cultured in
DMEM supplemented with 10% FBS and 5% P/S. Cell culture occurred within a 37 ⁰C
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sterile incubator at 5% CO2. When factor addition was considered, all media changes
occurred daily in the dark.

3.2.4 Scaffold Preparation for Cell Culture
Cylindrical scaffold sections, approximately 1 mm in length, were affixed with silicone
grease. 10 scaffolds per 3.5 cm culture dish or 1 scaffold per 96-well plate were used. The
scaffolds were immersed in EtOH overnight under UV light at RT in a sterile fume hood.
The EtOH was aspirated and replaced with HBSS for pre-conditioning at 37 ⁰C. Three
aspirations of the HBSS were completed over the course of 12 hours to ensure removal of
any residual EtOH.

3.2.5 2-D and 3-D Culture
Experiments in 2-D were carried out with hcSMCs seeded at densities of 250,000 cells/ 3.5
cm diameter dish. L-AA and/ or atRA addition occurred once the cells reached confluency
and was termed day 0 in biochemical factor related experiments. Experiments in 3-D were
carried out on hcSMCs and NIH-3T3 fibroblasts. The hcSMCs were seeded at a density of
450,000 cells/ scaffold. The NIH-3T3 fibroblasts were seeded at a density of 900,000 cells/
scaffold. Cells were allowed 24 hours for attachment prior to addition of L-AA and/ or
atRA which was termed day 0 in biochemical factor experiments.
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3.2.6 Cell Viability and Proliferation Assays
3.2.6.1 MTT
NIH-3T3 fibroblasts and hcSMCs were seeded onto 20%, 25%, and 30% PCL scaffolds
prepared w/w in EtOAc. Cell culture occurred for 4 and 7 days at which time the media
was aspirated and the cells were washed 1x gently in HBSS prior to the addition of 0.05%
Trypsin-EDTA solution and incubation at 37 ⁰C for 3 minutes. The solution was
centrifuged and the pellet re-suspended in phenol red free medium. Addition of the MTT
reagent, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, was added to each
well at a final concentration of 1.10 mM. The mixture was incubated at 37 ⁰C for 1 hour
proceeded by the addition of an equal volume of SDS (10% w/v in diH2O) and the
absorbance was read at 570 nm by a plate reader. The phenol red free medium was added
to each plate as a blank.

3.2.6.2 DNA Quantification
The proliferative capacity of hcSMCs was investigated using the CyQUANT ® cell
proliferation assay, obtained from Thermo Scientific, and following the manufacture’s
protocol. Briefly, primary hcSMCs were seeded at a density of 500 cells/ scaffold in 96well plates on 30% PCL scaffolds prepared w/w in EtOAc. After either 4 or 7 days, 0.05%
Trypsin-EDTA solution was added and the scaffolds were incubated at 37 ⁰C for 3 minutes.
Scaffolds were centrifuged for 5 minutes at 4000 rpm and the supernatant removed prior
to cellular pellet freezing at -80 ⁰C. CyQUANT GR dye/ cell-lysis buffer was added to the
pellets and fluorescence was read at 562 nm. A cell number standard curve allowed for
quantification of growth over time.
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3.2.7 Immunofluorescence Staining and Confocal Imaging in 3-D Culture
Cell cultures with primary hcSMCs on 3-D porous scaffolds were stained for F-actin and
nuclei prior to imaging. Cells were fixed in 4% Paraformaldehyde for 1 hour at RT prior
to cell permeabilization with 0.5% Triton X-100 for 10 minutes in 1x PBS. Following
permeabilization, 2x washing steps for 5 minutes were completed in 1x PBS. Incubation
for 1 hour at RT with diluted Alexa Fluor® 488 Phalloidin (1:50) in 1% BSA/PBS followed
with 2x subsequent washing steps in 1x PBS for 5 minutes. Incubation with secondary
antibody occurred for 1 hour at RT followed by 1x wash in 1x PBS for 5 minutes. DAPI
staining was done for 10 minutes at RT prior to 1x wash in 1x PBS for 5 minutes. Scaffolds
were affixed to glass microscope slides in mounting medium whereby spacers held the
samples in place. A Zeiss LSM 510 confocal microscope (Carl Zeiss, Germany) was
utilized in the imaging of the cells on the 3-D scaffolds.

3.2.8 RNA Isolation and Gene Expression Studies Using Real-Time PCR (qPCR)
Analysis
Real-time polymerase chain reaction (qPCR) was used to quantify mRNA expression of
GAPDH and elastin in primary hcSMCs seeded in 2-D culture. Total RNA was extracted
via Trizol® Reagent to which 0.50 μg glycogen was added during the purification as
described in the manufacture’s protocol. The RNA pellet produced during the purification
procedure was re-suspended in 20 μL dcpH2O and quantified using a NanoDrop Lite
Spectrophotometer. cDNA synthesis utilized 1 μg of total RNA, SsoAdvanced™ SYBR®
Green Supermix, and 20 μM of GAPDH and elastin forward and reverse primers. The
primers were as follows: GAPDH forward primer, 5’-GTT GGT CTC TGA CTT CAA
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CA-3’, and reverse primer, 5’-GTT GCT GTA GCC AAA TTC GTT GT-3’; elastin
forward primer, 5’-AAC CAG CCT TGC CCG C-3’, and reverse primer, 5’-CCC CAA
GCT GCC TGG TG-3’, were utilized.[140, 141] The qPCR protocol followed was specific for
the SsoAdvanced™ SYBR® Green Supermix as per Bio-Rad. Samples were prepared in
three replicates per experimental group and expression was normalized to GAPDH. Gene
expression Macro Analysis Software was utilized for quantification.

3.2.9 Protein Analysis Using Western Blotting
A Lysis Buffer (LB) was prepared with final concentrations of 1x proteinase inhibitor
cocktail, 1x PMSF, and 1x RIPA buffer all in diH2O. For 2-D culture, plates were washed
in 1x ice-cold PBS 3x prior to direct addition of LB to the culture plates followed by
scrapping and freezing at -80 ⁰C. For 3-D, the individual scaffolds were washed 3x in icecold 1x PBS prior to freezing at -80 ⁰C. Once frozen, scaffold pieces were cut using a
scalpel blade and added to LB and 3x freeze-thaw cycles occurred between -80 ⁰C and RT.
All subsequent work ensured protein samples were kept at least at 4 ⁰C. Centrifuging
occurred at 12,200 RPM at 4 ⁰C for 12 minutes. The supernatant was collected and diluted
1:4 for protein quantification based on a BSA standard curve read at 562 nm. Resolving
gels were prepared at 10% and stacking gels were prepared at 6%. Approximately 20-30
μg of total protein was loaded into the gels with each sample being composed of a final
concentration of 1x Laemmli Sample Buffer with 1% beta-mercaptoethanol. Samples were
heated at 95 ⁰C for 5 minutes and briefly micro-centrifuged prior to loading. SDS-gels were
run for 1 hour at 160 V. Transfer occurred for 1 hour at 90 V with numerous ice-packs to
ensure the temperature was low on the nitrocellulose membranes submerged in a Tris-
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glycine buffer containing 20% methanol. Ponceau S staining was subsequently utilized to
qualitatively assess transfer efficiency. Blocking the membrane occurred over 1 hour in a
solution containing 5% skim milk powder and 0.55% tween-20 in 1x PBS. Primary
antibody incubation occurred overnight at 4 ⁰C in incubation buffer consisting of 0.1%
skim milk powder and 0.11% tween-20 in 1x PBS. Primary antibody dilutions were made:
α-SMA (1:500), GAPDH (1:1000), and elastin (1:250). After overnight incubation, 3x
washing steps in incubation buffer occurred prior to incubation for 1 hour with HRPconjugated secondary antibodies diluted (1:250) in incubation buffer. A further 3x washing
steps in incubation buffer were completed prior to addition of the SuperSignal® West Pico
Chemiluminescent Substrate. A ChemiDoc™ XRS system, from BioRad, was used to
visualize the blots with further quantification occurring using ImageLab™ software.

3.2.10 Statistical Analysis
All protein quantification occurred using GraphPad Prism 5. Quantified data from qPCR
and western blotting experiments was normalized to controls with no factor treatment in
addition to GAPDH. Graphs were based on values obtained from three independent
experiments. The data is displayed as mean ± standard deviation. The data was statistically
analyzed by a one-way ANOVA proceeded by Tukey’s post hoc test or an unpaired
Student’s t-test. P-values of <0.05 were considered to be statistically significant.
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Chapter 4 – Results and Discussion
4.1 Scaffold Characterization
4.1.1 General Observations during Scaffold Fabrication
An ideal scaffold would be of comparable topography to that of the native ECM and
possess suitable porosity internally with lumenal and ablumenal surfaces conducive for cell
infiltration. An essential corollary to this notion is that the scaffold must possess the correct
micro-structure to allow for the required cell attachment and proliferation.[142]
Additionally, the scaffold should ideally be biodegradable with the degradation rate
matching cellular ECM production to maintain mechanical integrity. PCL has been shown
to meet the above requirements, with its in vivo degradation products being non-toxic while
possessing the ability to be enzymatically and hydrolytically degraded.[143, 144] However,
PCL degrades slowly (2-3 years) as the polymer is more so bioresorbable rather than
biodegradable.[144, 145] This may be advantageous as it provides sufficient time for cells to
regenerate their own ECM, if further in vivo remodeling is needed. That said, the optimal
amount of time to match ECM production rates with biodegradation remains unknown.[146]

Previous investigations using PCL have been focused on electrospinning applications
except a few studies which investigated PCL utilizing the SCPL process. Given the
limitations of cell infiltration with electrospinning[76] and the potential for the seeded cells
to therefore sense a more 2-D environment[147], it was thought that SCPL would be more
appropriate – especially when investigating cellular activity differences to biochemical
factors in 2-D compared to 3-D. Since PCL has not been extensively fabricated by SCPL,

43
there was a need to study this fabrication process. The variables considered in the SCPL
process are outlined in Table 4.1.

Table 4.1: Variables considered for solvent casting particulate leaching (SCPL) process to
fabricate PCL Scaffolds.
Variables
PCL concentration (w/w)

10, 15, 20, 25, 30%

Solvent

CHCl3, EtOAc, THF

Hold time in the tube (hours)

1, 2, 4, 6, 12, 24

Mandrel Materials

Teflon™ and stainless steel

Both tubular and rod-like scaffolds were fabricated. For the tubular scaffolds, a 4 mm
mandrel was utilized and the resulting scaffold possessed an approximate 0.5 mm wall
thickness to reflect the average size of a typical coronary vessel.[30] During scaffold
fabrication, the scaffolds were kept upright in a glass rod for 2 hours before removing them
from the mandrel and outer glass casing in order to evaporate part of the solvent and prevent
scaffold damage. The 2 hour hold time in the glass rod was found to be optimal as longer
times resulted in the scaffold hardening in the glass rod and thus was difficult to remove
without damage. Scaffolds removed with hold times less than 2 hours were too weak and
generally disintegrated upon removal. PCL concentrations greater than 30% were too
viscous to be poured over the porogen bed and those less than 20% produced scaffolds with
poor structural integrity and presented a challenge to consistently produce. Additionally,
the fabrication of the cylindrical rod-like scaffolds were found to require longer wait times
after removal from the scaffold fabrication chamber. This was likely due to the time needed
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to evaporate the solvent and, perhaps, for the PCL to undergo some recrystallization which
has been shown to generally result in an improvement of its mechanical properties.[148]

Regardless of initial PCL concentration for the rod-like cylindrical scaffolds, if these
scaffolds were inserted into the deionized H2O prematurely, the cross-sectional integrity
was compromised and overnight incubation at RT was the optimal way to prevent this
occurrence. An issue of structural/physical instability was observed in the rod-like
cylindrical scaffolds at 10% and 15% concentrations whereby an unexpected hollow
lumen-like structure was observed. This effect was seen with both hydrophobic (CHCl3
and EtOAc) and hydrophilic solvent (THF) systems. Although a structurally stable PCL
scaffold was not possible below a 20% concentration, Lin et al.[149] fabricated polyurethane
scaffolds at 15% concentrations in dimethylformamide. It is likely that the molecular
weight differences between these polymers represent one factor. The extensive hydrogen
bonding that exist within polyurethanes is also a factor since solution viscosity increases
with increased intermolecular forces.[150]

4.1.2 Scanning Electron Microscopy (SEM)
As the 2 hour hold time in the glass tube was optimal for the scaffold fabrication process,
this time was chosen for subsequent scaffold fabrications. The SEM images for the tubular
scaffolds are presented in Figures 4.1, 4.2. and 4.3. The ablumenal and lumenal surfaces
were examined for their porous morphology. It was thought that the SCPL process would
produce ablumenal and lumenal surfaces that were porous which would be beneficial for
cell seeding, infiltration, and mass transfer.[151] Additionally, having a more porous lumenal
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surface has been shown to make grafts less thrombogenic when implanted.[152] As the
porogen was in close proximity to the glass rod or central mandrel, this was thought to
facilitate an easier leaching out of the porogen and thus ensuring surface porosity. The
effects of the organic solvent used to prepare the solution and the PCL concentration on
the morphology of the tubular scaffolds is shown in Figures 4.1 and 4.2 respectively.

Figure 4.1: Ablumenal SEM images of 20-30% w/w PCL scaffolds fabricated using SCPL.
PCL was dissolved in CHCl3 (A-C), EtOAc (D-F) and THF (G-I). Scale bar represents 500
μm.
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Figure 4.2: Lumenal SEM images of 20-30% w/w PCL scaffolds fabricated using SCPL.
PCL dissolved in CHCl3 (A, B), EtOAc (C, D) and THF (E, F). Scale bar represents 1000
μm.

Regardless of solvent chosen and the PCL concentration, there appeared to be bubble-like
films on the ablumenal surfaces. Since it was expected that the SCPL would produce
scaffolds of varying porosity, the skin-like layer formation on the ablumenal surface was
not anticipated. Interestingly for the lumenal porosity, the 20% concentration was better
than the 30% concentration irrespective of the solvent used but these pores were isolated
and not interconnected. The challenge is that both the ablumenal and lumenal surfaces did
not produce consistently porous structures at all concentrations and instead
morphologically resembled films. Despite using ammonium chloride porogens, the
albumen and lumen morphologies observed in this study were consistent with a prior study
that showed the solvent utilized to dissolve PCL dictated the surface morphology of casted
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films due to the solubility of PCL in the various solvents with differences occurring at each
interface, either glass or air.[153] In this cited study, film microporosity was observed at the
polymer-glass interface when utilizing CHCl3 and THF but not EtOAc. However, in the
current study, all solvents appeared to produce similar effect on scaffold morphology when
in contact with the steel mandrel in the lumen or the glass tube in the ablumen. The
variation between the lumenal and the ablumenal surfaces likely reflect the different
surface properties between the two materials. Although surface contamination was a
possibility, both the glass rod and steel mandrel were washed in the respective solvent for
each specific run and left to air dry prior to use – making this unlikely to be a confounding
influence. To evaluate if the surface chemistry of the mandrel had any effect, a Teflon™
rod was utilized as a replacement for the steel mandrel on the basis of its low surface energy
which may alter interface phenomena.[154] However, similar morphological effects were
observed with the replacement mandrel (data not shown).

In addition to the lumen and albumen, the cross-section morphology was also investigated
(Figure 4.3). With the exception of scaffolds fabricated using THF as a solvent (Fig. 4.1 F,
H, I), all scaffolds were porous, interconnected, well-defined and open-faced. In the case
of THF, however, the pores were not interconnected and the pore interconnecting windows
were also sparse. A recent work by Choudhury et al.[155] suggested that the solvent may
play a significant role in altering the porosity of PLA scaffolds fabricated using SCPL. The
CHCl3 and EtOAc however appeared to produce cross-sectional areas with suitable
porosity and comparable morphology. Given the evaporation rate differences between the
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solvents used, the solvent-polymer interaction may be altered through thermodynamic
means during evaporation and this may affect scaffold morphology when THF was used.

Figure 4.3: SEM cross-sectional images of 20-30% w/w PCL tubular scaffolds fabricated
using SCPL. PCL was dissolved in CHCl3 (A-C); EtOAc (D-F) and THF (G-I). Scale bar
represents 500 μm.

4.1.3 Micro-CT analysis of 3-D Scaffolds
Since SEM is a qualitative technique, micro-computed tomography (micro-CT), which is
a non-destructive and quantitative imaging technique[156], was used. Representative micro-
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CT images and the quantification of scaffold morphology and features are presented in
Figure 4.4 and Table 4.2 respectively.

Figure 4.4: Micro-CT images of PCL scaffolds fabricated by dissolving in either CHCl3
or EtOAc at varying w/w concentrations. A-C. PCL dissolved in CHCl3. D-F. PCL
dissolved in EtOAc. The images are specific volume elements representing the crosssection within the scaffolds. The white within the image represents PCL and the grey
regions represent the pores.

Table 4.2: Micro-CT analysis of 3-D PCL scaffolds at varying w/w concentrations
dissolved in either CHCl3 or EtOAc. Two different scaffolds were fabricated and three
random measurements were taken for each scaffold (n = 6).
Solvent

EtOAc

CHCl3

PCL

Surface Area

Strut

Pore Diameter

Overall

Concentration

to Volume

Thickness

(μm)

Porosity (%)

(w/w)

Ratio (mm )

(μm)

20%

68.4±1.81

29.3±0.835

133±29.0

80.7±1.83

25%

63.9±6.85

31.5±3.43

137±7.88

81.1±2.72

30%

65.1±1.75

30.8±0.853

99.7±20.2

76.1±3.31

20%

53.6±0.114

37.4±0.0540

255±1.69

87.1±0.250

25%

55.9±1.27

35.8±0.811

123±0.348

77.4±0.474

30%

49.3±1.67

40.6±1.34

107±8.69

72.5±2.25

-1
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The effect of both polymer concentration and solvent used were determined by assessing
the overall porosity, strut thickness, surface area to volume ratio, and pore size. The need
to determine the scaffold parameters was based on the fact that the scaffold architecture is
related to not only the mechanical properties of the scaffold but also to the manner in which
cells would interact with the scaffold upon seeding.[156] All the scaffolds have sufficient
porosity (72% – 87%) suitable for cell seeding and infiltration and were within the range
of porosities that are often considered as ideal.[157] There is a clear trend that increasing
PCL concentration led to lower scaffold porosity and strut thickness which were expected.
The surface area to volume ratio of the scaffolds appeared to be dependent on the type of
solvent used instead of the PCL concentration where by scaffolds fabricated using EtOAc
had higher surface area to volume ratio than those fabricated using CHCl3. It is known that
for a scaffold needs to be highly porous while possessing a high surface area to volume
ratio to allow for suitable cell attachment and spreading.[158]

Surprisingly the pore

diameters obtained from micro-CT measurements were much lower than the particle size
of the porogens used (180 – 212 microns). This was not anticipated and the scaffold pore
sizes may be underestimated by the micro-CT measurements since NH4Cl particles are
insoluble in the organic solvents to explain size reduction during the scaffold fabrication
process. Based on overall scaffold features shown in Table 4.2, scaffolds fabricated from
30% PCL in EtOAc were chosen for subsequent cell culture studies.

4.2 Assessing Cell Viability and Proliferation
Cell viability was evaluated using two cell types: NIH-3T3 fibroblasts and hcSMCs. NIH3T3 fibroblasts were cultured on either 20%, 25%, or 30% PCL porous scaffolds for 4 or
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7 days in 96-well plates. The cells were seeded at 9 x 105 cells/scaffold and cultured without
additional biochemical factors. NIH-3T3 cells are known to proliferate faster than primary
cells[159]; thus NIH-3T3 cells could be least impacted by a change in the environment in
which they are seeded in and thus an MTT assay over 4 or 7 days would be suitable for an
assessment of viability.

As presented in Figure 4.5A, there was no significant difference in NIH-3T3 viability for
4 days and 7 days culture on both 25% and 30% PCL concentrations. However, at a PCL
concentration of 20%, there was a significant difference between day 4 and day 7 where
cells cultured for 7 days had increased metabolic activity. Furthermore, cells cultured on
30% PCL concentration for 7 days had significantly lower metabolic activity than those
cultured at 20% for 7 days. The cell viability assay was repeated on hcSMCs by seeding
4.5x105 cells/scaffold. As shown in Figure 4.5B, unlike the NIH-3T3 fibroblasts, the
hcSMCs viability increased both with PCL concentration and with increased culture time.
Unexpectedly, there appears to be a diverging trend on the metabolic activity the two cell
types tested. While NIH-3T3 cells were metabolically more active at 20% PCL
concentration, hcSMCs were more active at 30% PCL concentration. Although it remained
to be tested, cell spreading and phenotype variation may be one factor.
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Figure 4.5: MTT assays of NIH-3T3 fibroblasts or hcSMCs on 20%, 25%, or 30% w/w
PCL scaffolds dissolved in EtOAc. A: Viability of NIH-3T3 fibroblasts assessed at day 4
and 7. B: Viability of hcSMCs assessed at day 4 and 7. Significance: p<0.05 (*).

Varying the scaffold polymer concentration was thought to have a role in influencing the
ability of the cells to adhere to the scaffold and proliferate. In hydrogel systems, increasing
the polymer concentrations within scaffolds can significantly reduce cell viability.[160]
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However, the likely reason to this in hydrogel systems are the higher cross-linking densities
which limit the mass transfer characteristics.[161] In electrospinning systems, increasing the
polymer concentration can result in a non-linear relationship between solution
concentration and fiber diameter whereas increased fibers diameters result in lower
viability.[162] However, there was no study found in the literature of cell viability in the
SCPL process at various polymer concentrations which is surprising given that scaffold
architecture is paramount to cellular behavior.[156]

To evaluate if the increase in viability of the hcSMCs correlated with that of an increase in
proliferation, DNA quantification was conducted. It is known that an MTT metabolic assay
does not always parallel observations seen in the more quantitative DNA assay in 3-D
cultures.[163] As the 30% PCL concentration showed significantly higher hcSMCs viability,
it was chosen to for cell proliferation study. The proliferation of the hcSMCs seeded on the
30% PCL concentration at days 4 and 7 is shown in Figure 4.6. By day 7, the cell number
was significantly higher than day 4, confirming the trend suggested by the MTT data and
ability of the 30% PCL scaffolds to support and promote proliferation over time.
Considering both the MTT and DNA quantification data, the 30% PCL scaffolds prepared
in EtOAc were deemed to support cell viability and growth over time most optimally and
were utilized in subsequent cell culture experiments.
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Figure 4.6: DNA quantification of hcSMCs seeded onto 30% w/w PCL scaffolds at days
4 and 7. Significance: p<0.05 (*), p<0.01 (**), p<0.001 (***).

4.3 The Effect of atRA on Cultured Smooth Muscle Cells
4.3.1 Cell Morphological Response to atRA Treatment
Before studying the effect was atRA on elastin expression on PCL scaffolds, it was thought
that any potential toxic effects that atRA may have on the hcSMCs should be explored.
While most studies occurred in 2-D cultures, one prior study investigated atRA treatment
on vSMCs in 3-D culture using aortic SMCs.[138] In a direct comparison with non-coronary
medial SMCs, it was found that hcSMCs may differ in gene expression and response to
biochemical factor treatment in culture.[164] Additionally, it is known that the response to
factors can vary between 2-D and 3-D microenvironments. Lin et al. demonstrated that
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hcSMCs can vary in their response to TGF-β1, with a more pronounced elastogenic
response in 3-D than 2-D culture.[111] Since there are no prior studies about the effect of
atRA on the viability of hcSMCs seeded onto 3-D porous scaffolds, it seemed reasonable
to assess its suitability. In order to have a clean system that does not confound results, a
non-degradable polyurethane scaffold was fabricated in the same way as the PCL scaffolds.
There are no degradation products in this polyurethane (at least in the short term); thus cell
phenotype will not be affected and does not confound results as per previous publications
from Mequanint's lab

[111, 139, 149, 158, 165, 166]

. There is little difference between the model

polyurethane scaffold and PCL in terms of hydrophobicity indicating that cells would not
significantly favor one polymer over the other for cell adhesion. Additionally, both were
pre-conditioned in buffer which has been shown to increase the hydrophilicity of the
polymers and improve cell viability.[167]

100 μM of atRA concentration was added to hcSMCs seeded on porous polyurethane
scaffolds and confocal images were taken after culturing for 4 and 7 days. The confocal
images presented in Figure 4.7 revealed that hcSMCs formed a dense layer surrounding
the scaffold struts with no indication of cytoskeletal or DNA fragmentation. At day 7, cells
were observed bridging the scaffold pores suggesting active migration.
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Figure 4.7: Confocal images of hcSMCs seeded onto porous 3-D polyurethane scaffolds
and exposed to 100 μM of atRA. Confocal images were taken after 4 and 7 days of culture.
Scale bar represents 200 μm. Staining: F-actin (green) and DAPI (red).
While 100 μM of atRA appeared to support growth and suitable spreading by day 7, the
effect of fibronectin coating and cultures longer than 7 days were studied. The rationale for
fibronectin coating was that, it is a frequently used ECM component to enhance cell
attachment and spreading on scaffolds through its RGD motif that can facilitate integrin
binding.[168,

169]

There are many studies that utilize fibronectin to increase cellular

attachments to scaffolds to accelerate favorable cell-scaffold interactions.[169-171] The
rationale for longer time culture (14 days) was that cells may respond differently to
sustained atRA treatment compared to shorter times. Figure 4.8 displays confocal images
of hcSMCs at day 14 on the porous 3-D model polyurethane scaffold. While cells were
observed spreading on the fibronectin-coated scaffolds with abundant F-actin, the
treatment of cells with 150 μM atRA resulted in diminished F-actin suggesting cell death.
It is suggested that atRA can increase the expression of β1-integrin which can interact
strongly with fibronectin.[172]
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Figure 4.8: Confocal images of hcSMCs seeded on a porous 3-D polyurethane scaffold
with or without fibronectin pre-treatment and 150 μM atRA. Cells were cultured for 14
days before fixation and confocal imaging. Scale bar represents 200 μm. Staining: F-actin
(green) and DAPI (red).

It is worthy to note that cells had similar morphology and density regardless of fibronectin
treatment. In view of this and since fibronectin may play a role in influencing elastin
synthesis by shifting vSMCs into a more synthetic phenotype [173], its presence may further
confound the effect of atRA and therefore, was precluded from further studies. Grenier et
al.[166] found that when hcSMCs were cultured on fibronectin coated porous 3-D scaffolds,
the expression of vSMC contractile phenotypic markers was reduced. As elastogenesis is
known to likely be enhanced in the synthetic state, fibronectin may influence the way in
which cells respond to biochemical factor stimulation in the context of elastin expression.
While the design of the current study was focused on assessing differences between 2-D
and 3-D microenvironments and how cell responses will vary to biochemical factor
exposure, future studies may investigate the impact that various coatings would have on
elastogenesis. While Grenier et al.[166] focused on fibronectin and Matrigel coatings, that
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study did not assess elastin at the transcriptional or translational level. The impact of
understanding how coating with ECM proteins could increase elastogenesis may be
invaluable for future experimental designs attempting to augment elastogenesis for VTE.

4.3.2 The effect of atRA Concentration on Elastin Gene Expression
The concentration of atRA may affect tropoelastin transcription in a dose-dependent
manner. To test this, hcSMCs were seeded in 2-D culture plates and were treated with
different concentrations of atRA (0.1 to 10 M) over 4 days culture. While it can be
expected that the elastogenic effect of atRA may vary temporally, the response to varying
concentrations should be consistent with time. As shown in Figure 4.9, the concentration
that promoted the highest fold increase in tropoelastin transcription occurred when using
10 μM atRA; producing a 2-fold increase in gene expression. While 0.1 and 1 μM atRA
also increased tropoelastin mRNA levels compared to the untreated control, the fold
increase was not significant. Based on the observations of Figures 4.7 and 4.8, it was
tempting to increase the atRA concentration to boost elastin in the gene expression study.
Although 100 μM and 150 μM were investigated for the confocal studies, these
concentrations are not physiological and may have other negative effects beyond boosting
elastin expression. Therefore, it was decided to limit the gene/protein expression studies to
reported physiological atRA concentration ranges.[113] Not withstanding this, higher
concentration of atRA would be tolerated in vivo, as documented for acute promyelocytic
leukemia chemotherapy.[174] In vitro studies suggested that utilizing higher atRA
concentrations would result in a decrease in vSMC proliferative ability which emphasized
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the need to select a lower concentration while still facilitating the highest increase in
tropoelastin transcriptional activity.[123, 175]

Figure 4.9: The effect of atRA concentration on tropoelastin gene expression in hcSMCs
cultured on 2D plates for 4 days. 10 μM atRA produced the highest tropoelastin fold
increase and was utilized for subsequent experiments. Significance: p<0.05 (*) was
observed for 10 μM of atRA compared to the untreated control (C) and 0.1 and 1 μM of
atRA.
4.4 The Effect of AA and atRA Combination on Tropoelastin Synthesis
As the concentration of atRA in gene expression experiments was maximum at 10 μM, the
effect on tropoelastin protein expression due to a combined treatment of AA and atRA was
investigated. Although AA has been reported to decrease elastogenesis in 2-D cultures[137],
the rationale behind the biochemical factor’s use was to increase collagen expression[136,
137]

since both elastin and collagen are essential ECM components of a vascular tissue.

Thus, as atRA has been reported to increase elastin [133], it was necessary to investigate the
interaction between the two biochemical factors. However, there have been limited studies
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investigating the effect of the combination of AA and atRA on elastogenesis in hcSMCs
with the work by Ogle et al. being the lone consideration.[138] Ideally, the ability to increase
elastin with combined biochemical factor treatment would enhance vascular tissue
fabrication. Thus, the premise of the investigation was that while atRA and AA would show
an increase and decrease in elastin expression respectively, it was unknown to what effect
the combination would have. To test this, a time-course experiment (24 hours – 96 hours)
was conducted in 2-D culture plates after the cells had reached confluence. The reason for
reaching cell confluency before biochemical factors treatment was to limit the effect of
phenotypic modulation in culture.[24]

As shown in Figure 4.10, the increased tropoelastin expression when supplemented with
atRA was significantly higher at all time points relative to AA alone. Conversely, AA
decreased elastin expression compared with atRA alone at all time-points. The combined
AA and atRA treatment significantly decreased tropoelastin synthesis at all time points.
This suggested that the effect of the combination was influenced to a greater extent by AA
as no significant differences were observed between AA and the combination at the tested
time-points while significance occurred between atRA alone and the combined treatment.
It was suspected that AA may be exerting its effects at an earlier stage of tropoelastin
synthesis whereas atRA functions at a later stage. For instance, studies suggested that atRA
may influence tropoelastin mRNA stability while it is known that AA may exert its effect
earlier, directly at the transcriptional level.[137]
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Figure 4.10: Time-course evaluation tropoelastin synthesis (as determined by Western
blot) isolated from whole-cell lysates of hcSMCs in response to various biochemical factor
treatments. Data are normalized to GAPDH and a control without biochemical factor
treatment. Significance: p<0.05 (*) was observed as indicated in the graph.

It seems likely that less tropoelastin mRNA may be produced for the atRA to stabilize
which may account for the similar protein expression patterns generally observed between
AA and the combination treatment. To evaluate this possibility, tropoelastin transcription
experiments at 48, 72, and 96 hours were conducted. As shown in Figure 4.11 the
tropoelastin mRNA expression levels were not significantly different compared with the
control at 72 and 96 hours, which correlated with the protein expression levels seen in
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Figure 4.10. However, there was a significant increase (5.5-fold increase) at the 48 hour
time point. Taken together, this may suggest that while temporal variation exists in terms
of transcriptional activity, the effect of the decrease in tropoelastin protein expression with
combined atRA and AA treatment is very likely attributed to transcriptional repression.

Figure 4.11: qPCR assessing tropoelastin transcription in hcSMCs at 48, 72, and 96 hours
comparing a combination of AA and atRA to a non-treated control, both normalized to
GAPDH. Significance: p<0.05 (*) was observed for the combination treatment relative to
the untreated control at the 48-hour time point. NS: Not significant.

4.5 Comparative Study of Elastin Synthesis in 2D Plates and 3D PCL Scaffolds
4.5.1 Spatial Effects on Elastin Synthesis
The effect of the culture microenvironment on elastin synthesis was evalauted at days 4
and 7 by seeding the hcSMCs onto 2-D culture plates and 3-D porous PCL scaffolds.
Elastin expression at days 4 and 7 in 2-D and 3-D cultures is shown in Figure 4.12.
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Figure 4.12: Western blotting of whole-cell lysates of hcSMCs assessing for tropoelastin
expression in response to biochemical factor treatment in 2D culture plates (A) and 3D
PCL scaffolds (B). Data was normalized to GAPDH and a non-treated control.
Significance: p<0.05 (*).

Two observations can be made from Figure 4.12: (i) The protein expression levels had
similar patterns between 2-D and 3-D, and (ii) similar to short culture times (Figure 4.10),
the combined treatment reduced elastin expression in 3-D. This suggests that although the
cells are seeded in different environments, the effects of the biochemical factor stimulation
on elastin expression are not spatially dependent. Notwithstanding this, the amount of
elastin produced was more pronounced in 3-D. This is consistent with work by Lin et al.[111]
who suggested that the 3-D environment alone is sufficient to increase elastin expression
relative to 2-D cultures. However, the effect of AA in 3-D cultures appears to be low
compared to 2-D cultures at day 4. By day 7, the lowering of elastin protein expression in
response to AA treatment or a combination with atRA was alleviated and rose to levels
similar to those seen in the non-treated controls. While the experimental time-point ended
at day 7, it would be interesting to study if the reduction seen in 3-D compared to atRA
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alone would be overcome at longer time-points. Previous work by Ogle et al.

[138]

examining the combination treatment in 3-D did not investigate the impact of atRA or AA
alone on elastin protein expression in 3-D and thus it is difficult to make direct comparison.

4.5.2 Combinational Approach to Rescue Elastin Expression in 3-D Culture
The decrease in elastin protein expression with the combination treatment compared to that
of atRA alone was unfortunate as both factors are required for either increasing collagen
or elastin and are thus necessary for engineering viable vascular tissues. As the experiments
in both 2-D and 3-D suggested that AA was lowering elastin synthesis, a new approach
was devised. To maintain the elastogenic effect of atRA while preserving the ability of AA
to increase collagen expression, a sequential treatment was attempted. AA was initially
supplemented to increase collagen expression prior to stopping AA stimulation and
providing atRA treatment. This was implemented to test if elastin expression can be
rescued after the expected decrease in response to AA treatment. As Figure 4.13
demonstrates, the effect of AA seemed to have a significant impact on elastin expression
even when the AA was removed from the culture environment. Removal of AA for 1 and
3 days did not result in a significant difference compared to the control over the 7 days
culture. This suggests that both 1 day and 3 days exposure was not sufficient produce
elastin at the level observed when atRA was added alone over 4 day assay (compare Fig
4.13 with Fig 4.10 and 4.12). However, there was a significant difference between AA
treatment alone over the 7 days and 3 days of rescue with the atRA. This suggested that the
repression on elastin synthesis induced by AA can be overcome by subsequent addition
atRA, though it may take longer than 1 day to observe an effect.
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Figure 4.13: Elastin expression assessed by Western blotting of whole-cell lysates of
hcSMCs after sequential non-overlapping factor exposure for different times. The
schematic of the experimental design is shown in A where cells were cultured either
without treatment (control), 6 days of AA treatment, 5 days AA followed by 1 day atRA
treatment or 3 days AA followed by 3 days atRA treatment. Cells were harvested on the
7th day for protein extraction and Western blotting. Significance: p<0.05 (*) was observed
for 3 days of atRA rescue compared to AA alone.
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It is possible that the collagen expression stimulated by AA may have suppressed elastin
expression and this is plausible. Although collagen gels are commonly utilized in VTE they
have been shown to suppress elastogenic effects in vitro.[11] Another possibility for this
temporal suppression could be that some AA is adsorbed onto the surfaces of the PCL
scaffold and acted on the smooth muscle cells for longer times than anticipated. However,
given the rapid oxidation of AA in tissue culture environments, this is unlikely.[176] This
suggests that AA may have delayed inhibitory effects on elastogenesis. It would be
interesting to examine the effect of atRA treatment first followed by AA on elastin and
collagen synthesis or using a longer sequential non-overlapping factor exposure to observe
if the AA mediated decrease can be mitigated with time.

4.5.3 The Effect of Biochemical Factors on α-SMA Expression
As there is a known correlation with ECM synthesis and vSMC phenotype, the effect of
biochemical factor stimulation on the phenotype was investigated in both 2-D and 3-D
cultures. However, when assessing vSMC phenotypic plasticity, it is known that there can
be significant heterogeneity within a culture, thus making the phenotype difficult to
assess.[177] In spite of this, atRA has been shown to induce vSMCs to progress to a more
contractile phenotype in 2-D.[118, 119] There is no data on the effect that AA may have on
vSMC phenotype in 3-D cultures. As AA reduced elastin protein expression at both day 4
and day 7, the role of AA in cell phenotype was investigated (Figure 4.14). While there are
numerous contractile protein markers, α-SMA is associated with an earlier/mid stage
differentiation marker was chosen in comparison to the more mature markers such as
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smooth muscle myosin-heavy chain which occur at later time-points.[105] It was thought
that α-SMA would indicate the onset of transition to the contractile phenotype.

Figure 4.14: Western blotting of whole-cell lysates of hcSMCs assessing for α-SMA
normalized to GAPDH at day 4 and day 7 cultures for 2D cultures (A, B) and 3D cultures
(C, D). Significance: p<0.05 (*).
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In 2-D, α-SMA expression levels were similar across treatment groups at both day 4 and
day 7; however, α-SMA expression was significantly higher on the 3-D combination
treated cultures at day 7 than all other treatments. This suggests that elastin expression in
2-D may be independent from the adoption of a contractile phenotype when treated with
AA alone or in combination with atRA. Moreover, the lack of significance for all
biochemical factor treatments relative to the controls at both day 4 and day 7 indicates that
in 2-D these biochemical factors possess little phenotypic influence compared to the
seeding environment alone. Generally stiffer substrates induce a more synthetic
phenotype.[106] It appears that AA or the combination treatment have no effect on α-SMA
expression in both 2-D and 3-D cultures to induce the contractile phenotype. As atRA was
expected to promote the contractile state, in 2-D, the AA mediated influence on low elastin
expression appears to be potentially dependent on phenotype. The current data is consistent
with a study conducted by Ryan et al.[178] who suggested that in collagen gels, insoluble
elastin can induce a contractile phenotype characterized by an increase in α-SMA.
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Chapter 5 – Conclusions and Future
Directions
5.1 Conclusions
The present study assessed the SCPL process for PCL scaffold fabrication. The scaffolds
were then utilized for culturing smooth muscle cells with biochemical factors to enhance
elastin synthesis. The initial scaffold fabrication considered PCL dissolved in varying
concentrations and solvents. It was found that a hold time of 2 hours in the glass rod
produced the best scaffolds as shorter times led to disintegration and longer times resulted
in an inability to remove the scaffold from the glass tube casing irrespective of solvent
chosen and concentration of PCL. However, the type of the solvent was found to influence
the morphology of the scaffolds. SEM studies showed that THF produced scaffolds that
have poorly-interconnected and closed pores. In tubular scaffolds, all solvents produced
bubble-like films on the ablumen and isolated pores in the lumen regardless of the PCL
concentration. Micro-CT was used to identify EtOAc as the best solvent to fabricate the
PCL scaffolds based on overall porosity, strut thickness, and surface area to volume ratio.
Given the higher ratios obtained with EtOAc as the solvent, it was used in the scaffold
fabrication for subsequent cell culture studies. MTT assay using NIH-3T3 fibroblasts and
hcSMCs on PCL scaffolds fabricated from 20, 25, 30% concentration showed an opposite
trend as a function of PCL used to fabricate the scaffolds likely due to differences in
metabolic activity and proliferation rate between the two cell lines. While 30% resulted in
significantly less viability than seen with 20% for the NIH-3T3 fibroblasts, 30% promoted
the highest viability with hcSMCs which was confirmed with a more quantitative DNA
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assay. Given the higher viability and proliferation observed with the hcSMCs and as the
30% PCL concentration was more mechanically stable, it was chosen for elastogenic
studies. qPCR confirmed that 10 μM atRA promoted the highest tropoelastin
transcriptional activity and confocal imaging on model polyurethane scaffolds indicated
that higher concentrations at day 4 and 7 produced no cytotoxic effects. To evaluate the
effect of AA and atRA, Western blotting of whole-cell lysates for tropoelastin was
conducted. Significant increases in relative expression when treated with atRA alone
occurred at 48 and 96 hours indicating that temporal variation exists in the elastogenic
effect of atRA. However, the combination of AA and atRA expression more closely
mirrored that of AA alone which indicated that AA may have a greater effect than atRA in
2-D cultures. Similar trends were observed when comparing tropoelastin expression in 2D culture plates and 3-D PCL scaffolds, with atRA treatment alone significantly increasing
expression compared to AA alone or the combination at both day 4 and day 7 in 3-D and
day 7 in 2-D. Interestingly, when assessing whether this trend correlated with the
phenotype of the hcSMCs in both 2-D and 3-D it was found that α-SMA remained constant
in 2-D yet was increased over time with AA alone and the combination treatment. Given
the decrease in elastin when combination treatment was used, a sequential treatment was
shown to be effective to enhance elastin synthesis. Overall, the study in this thesis provided
insights into early responses of hcSMCs on SCPL PCL scaffolds and elastin synthesis in
response to atRA and AA.
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5.2 Future Directions
Moving forward, the following future studies are suggested:


Conduct long-term cultures using the sequential addition of biochemical factors.



Combine biochemical factors with biomechanical forces to study the possible
synergy between them



Understand molecular mechanisms of elastin synthesis in response to atRA in 3-D
cultures.

72

6. References
[1] N.J. Pagidipati, T.A. Gaziano, Estimating deaths from cardiovascular disease: a review
of global methodologies of mortality measurement, Circulation 127(6) (2013) 749-56.
[2] J. Jin, G.E. Sklar, V. Min Sen Oh, S. Chuen Li, Factors affecting therapeutic
compliance: A review from the patient's perspective, Ther Clin Risk Manag 4(1) (2008)
269-86.
[3] S. Pashneh-Tala, S. MacNeil, F. Claeyssens, The Tissue-Engineered Vascular GraftPast, Present, and Future, Tissue Eng Part B Rev (2015).
[4] P.J. Wiegman, W.L. Barry, J.A. McPherson, C.A. McNamara, L.W. Gimple, J.M.
Sanders, G.G. Bishop, E.R. Powers, M. Ragosta, G.K. Owens, I.J. Sarembock, All-transretinoic acid limits restenosis after balloon angioplasty in the focally atherosclerotic rabbit
: a favorable effect on vessel remodeling, Arterioscler Thromb Vasc Biol 20(1) (2000) 8995.
[5] J.E. Wagenseil, R.P. Mecham, Vascular extracellular matrix and arterial mechanics,
Physiol Rev 89(3) (2009) 957-89.
[6] G.G. Belz, Elastic properties and Windkessel function of the human aorta, Cardiovasc
Drugs Ther 9(1) (1995) 73-83.
[7] R.K. Jain, Molecular regulation of vessel maturation, Nat Med 9(6) (2003) 685-93.
[8] A.V. Kamenskiy, Y.A. Dzenis, J.N. MacTaggart, T.G. Lynch, S.A. Jaffar Kazmi,
Pipinos, II, Nonlinear mechanical behavior of the human common, external, and internal
carotid arteries in vivo, J Surg Res 176(1) (2012) 329-36.
[9] N. Thottappillil, P.D. Nair, Scaffolds in vascular regeneration: current status, Vasc
Health Risk Manag 11 (2015) 79-91.
[10] S.L. Sandow, D.J. Gzik, R.M. Lee, Arterial internal elastic lamina holes: relationship
to function?, J Anat 214(2) (2009) 258-66.
[11] A. Patel, B. Fine, M. Sandig, K. Mequanint, Elastin biosynthesis: The missing link in
tissue-engineered blood vessels, Cardiovasc Res 71(1) (2006) 40-9.
[12] G.A. Holzapfel, H.W. Weizsacker, Biomechanical behavior of the arterial wall and its
numerical characterization, Comput Biol Med 28(4) (1998) 377-92.
[13] A.G. Vouyouka, B.J. Pfeiffer, T.K. Liem, T.A. Taylor, J. Mudaliar, C.L. Phillips, The
role of type I collagen in aortic wall strength with a homotrimeric, J Vasc Surg 33(6) (2001)
1263-70.
[14] A. Bigi, A. Ripamonti, N. Roveri, X-ray diffraction and scanning electron microscopy
of bovine media aortic wall, Connect Tissue Res 5(1) (1977) 37-9.

73
[15] A.P. Ebrahimi, Mechanical properties of normal and diseased cerebrovascular system,
J Vasc Interv Neurol 2(2) (2009) 155-62.
[16] M.J. Chow, R. Turcotte, C.P. Lin, Y. Zhang, Arterial extracellular matrix: a
mechanobiological study of the contributions and interactions of elastin and collagen,
Biophys J 106(12) (2014) 2684-92.
[17] J.E. Wagenseil, R.P. Mecham, New insights into elastic fiber assembly, Birth Defects
Res C Embryo Today 81(4) (2007) 229-40.
[18] D.V. Bax, U.R. Rodgers, M.M. Bilek, A.S. Weiss, Cell adhesion to tropoelastin is
mediated via the C-terminal GRKRK motif and integrin alphaVbeta3, J Biol Chem 284(42)
(2009) 28616-23.
[19] D.J. Johnson, P. Robson, Y. Hew, F.W. Keeley, Decreased elastin synthesis in normal
development and in long-term aortic organ and cell cultures is related to rapid and selective
destabilization of mRNA for elastin, Circ Res 77(6) (1995) 1107-13.
[20] M.H. Swee, W.C. Parks, R.A. Pierce, Developmental regulation of elastin production.
Expression of tropoelastin pre-mRNA persists after down-regulation of steady-state
mRNA levels, J Biol Chem 270(25) (1995) 14899-906.
[21] J. Uitto, S. Hsu-Wong, S.D. Katchman, M.M. Bashir, J. Rosenbloom, Skin elastic
fibres: regulation of human elastin promoter activity in transgenic mice, Ciba Found Symp
192 (1995) 237-53; discussion 253-8.
[22] H. Umeda, M. Aikawa, P. Libby, Liberation of desmosine and isodesmosine as amino
acids from insoluble elastin by elastolytic proteases, Biochem Biophys Res Commun
411(2) (2011) 281-6.
[23] M.J. Rock, S.A. Cain, L.J. Freeman, A. Morgan, K. Mellody, A. Marson, C.A.
Shuttleworth, A.S. Weiss, C.M. Kielty, Molecular basis of elastic fiber formation. Critical
interactions and a tropoelastin-fibrillin-1 cross-link, J Biol Chem 279(22) (2004) 2374858.
[24] Y. Cao, Y.F. Poon, J. Feng, S. Rayatpisheh, V. Chan, M.B. Chan-Park, Regulating
orientation and phenotype of primary vascular smooth muscle cells by biodegradable films
patterned with arrays of microchannels and discontinuous microwalls, Biomaterials 31(24)
(2010) 6228-38.
[25] S. Kyle, A. Aggeli, E. Ingham, M.J. McPherson, Production of self-assembling
biomaterials for tissue engineering, Trends Biotechnol 27(7) (2009) 423-33.
[26] L. Cardamone, A. Valentin, J.F. Eberth, J.D. Humphrey, Origin of axial prestretch and
residual stress in arteries, Biomech Model Mechanobiol 8(6) (2009) 431-46.

74
[27] C.A. Taylor, J.D. Humphrey, Open Problems in Computational Vascular
Biomechanics: Hemodynamics and Arterial Wall Mechanics, Comput Methods Appl Mech
Eng 198(45-46) (2009) 3514-3523.
[28] T.R. Cox, J.T. Erler, Remodeling and homeostasis of the extracellular matrix:
implications for fibrotic diseases and cancer, Dis Model Mech 4(2) (2011) 165-78.
[29] M. Loukas, A. Sharma, C. Blaak, E. Sorenson, A. Mian, The clinical anatomy of the
coronary arteries, J Cardiovasc Transl Res 6(2) (2013) 197-207.
[30] J.T. Dodge, Jr., B.G. Brown, E.L. Bolson, H.T. Dodge, Lumen diameter of normal
human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular
hypertrophy or dilation, Circulation 86(1) (1992) 232-46.
[31] I. Ozolanta, G. Tetere, B. Purinya, V. Kasyanov, Changes in the mechanical
properties, biochemical contents and wall structure of the human coronary arteries with age
and sex, Med Eng Phys 20(7) (1998) 523-33.
[32] A.K. Hiteshi, D. Li, Y. Gao, A. Chen, F. Flores, S.S. Mao, M.J. Budoff, Gender
differences in coronary artery diameter are not related to body habitus or left ventricular
mass, Clin Cardiol 37(10) (2014) 605-9.
[33] C.V. Bouten, P.Y. Dankers, A. Driessen-Mol, S. Pedron, A.M. Brizard, F.P. Baaijens,
Substrates for cardiovascular tissue engineering, Adv Drug Deliv Rev 63(4-5) (2011) 22141.
[34] C.J. van Andel, P.V. Pistecky, C. Borst, Mechanical properties of porcine and human
arteries: implications for coronary anastomotic connectors, Ann Thorac Surg 76(1) (2003)
58-64; discussion 64-5.
[35] G. Heusch, Heart rate in the pathophysiology of coronary blood flow and myocardial
ischaemia: benefit from selective bradycardic agents, Br J Pharmacol 153(8) (2008) 1589601.
[36] D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, S.R.
Das, S. de Ferranti, J.P. Despres, H.J. Fullerton, V.J. Howard, M.D. Huffman, C.R. Isasi,
M.C. Jimenez, S.E. Judd, B.M. Kissela, J.H. Lichtman, L.D. Lisabeth, S. Liu, R.H.
Mackey, D.J. Magid, D.K. McGuire, E.R. Mohler, 3rd, C.S. Moy, P. Muntner, M.E.
Mussolino, K. Nasir, R.W. Neumar, G. Nichol, L. Palaniappan, D.K. Pandey, M.J. Reeves,
C.J. Rodriguez, W. Rosamond, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani,
D. Woo, R.W. Yeh, M.B. Turner, Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association, Circulation 133(4) (2016)
447-54.
[37] P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup, M.D. Ezekowitz,
E.A. Finkelstein, Y. Hong, S.C. Johnston, A. Khera, D.M. Lloyd-Jones, S.A. Nelson, G.
Nichol, D. Orenstein, P.W. Wilson, Y.J. Woo, Forecasting the future of cardiovascular

75
disease in the United States: a policy statement from the American Heart Association,
Circulation 123(8) (2011) 933-44.
[38] G.K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N Engl J
Med 352(16) (2005) 1685-95.
[39] S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, J. Halsey, N.
Qizilbash, R. Peto, R. Collins, Blood cholesterol and vascular mortality by age, sex, and
blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000
vascular deaths, Lancet 370(9602) (2007) 1829-39.
[40] B.V. Howard, D.C. Robbins, M.L. Sievers, E.T. Lee, D. Rhoades, R.B. Devereux,
L.D. Cowan, R.S. Gray, T.K. Welty, O.T. Go, W.J. Howard, LDL cholesterol as a strong
predictor of coronary heart disease in diabetic individuals with insulin resistance and low
LDL: The Strong Heart Study, Arterioscler Thromb Vasc Biol 20(3) (2000) 830-5.
[41] P. Sun, K.M. Dwyer, C.N. Merz, W. Sun, C.A. Johnson, A.M. Shircore, J.H. Dwyer,
Blood pressure, LDL cholesterol, and intima-media thickness: a test of the "response to
injury" hypothesis of atherosclerosis, Arterioscler Thromb Vasc Biol 20(8) (2000) 200510.
[42] J. Davignon, P. Ganz, Role of endothelial dysfunction in atherosclerosis, Circulation
109(23 Suppl 1) (2004) III27-32.
[43] N.A. Shirwany, M.H. Zou, Arterial stiffness: a brief review, Acta Pharmacol Sin
31(10) (2010) 1267-76.
[44] W.C. Morgan, H.L. Hodge, Diagnostic evaluation of dyspnea, Am Fam Physician
57(4) (1998) 711-6.
[45] J.M. Schussler, Effectiveness and safety of transradial artery access for cardiac
catheterization, Proc (Bayl Univ Med Cent) 24(3) (2011) 205-9.
[46] D.G. Katritsis, J.P. Ioannidis, Percutaneous coronary intervention versus conservative
therapy in nonacute coronary artery disease: a meta-analysis, Circulation 111(22) (2005)
2906-12.
[47] J.W. Jukema, J.J. Verschuren, T.A. Ahmed, P.H. Quax, Restenosis after PCI. Part 1:
pathophysiology and risk factors, Nat Rev Cardiol 9(1) (2011) 53-62.
[48] V. Farooq, B.D. Gogas, P.W. Serruys, Restenosis: delineating the numerous causes of
drug-eluting stent restenosis, Circ Cardiovasc Interv 4(2) (2011) 195-205.
[49] G.D. Dangas, B.E. Claessen, A. Caixeta, E.A. Sanidas, G.S. Mintz, R. Mehran, Instent restenosis in the drug-eluting stent era, J Am Coll Cardiol 56(23) (2010) 1897-907.

76
[50] J.M. Bourget, R. Gauvin, D. Larouche, A. Lavoie, R. Labbe, F.A. Auger, L. Germain,
Human fibroblast-derived ECM as a scaffold for vascular tissue engineering, Biomaterials
33(36) (2012) 9205-9213.
[51] A.R. Halabi, J.H. Alexander, L.K. Shaw, T.J. Lorenz, L. Liao, D.F. Kong, C.A.
Milano, R.A. Harrington, P.K. Smith, Relation of early saphenous vein graft failure to
outcomes following coronary artery bypass surgery, Am J Cardiol 96(9) (2005) 1254-9.
[52] P.W. Serruys, M.C. Morice, A.P. Kappetein, A. Colombo, D.R. Holmes, M.J. Mack,
E. Stahle, T.E. Feldman, M. van den Brand, E.J. Bass, N. Van Dyck, K. Leadley, K.D.
Dawkins, F.W. Mohr, Percutaneous coronary intervention versus coronary-artery bypass
grafting for severe coronary artery disease, N Engl J Med 360(10) (2009) 961-72.
[53] M. Lovett, K. Lee, A. Edwards, D.L. Kaplan, Vascularization strategies for tissue
engineering, Tissue Eng Part B Rev 15(3) (2009) 353-70.
[54] S.H. Ku, C.B. Park, Human endothelial cell growth on mussel-inspired nanofiber
scaffold for vascular tissue engineering, Biomaterials 31(36) (2010) 9431-7.
[55] I.L. Geenen, D.G. Molin, N.M. van den Akker, F. Jeukens, H.M. Spronk, G.W.
Schurink, M.J. Post, Endothelial cells (ECs) for vascular tissue engineering: venous ECs
are less thrombogenic than arterial ECs, J Tissue Eng Regen Med 9(5) (2015) 564-76.
[56] X. Chen, A.S. Aledia, S.A. Popson, L. Him, C.C. Hughes, S.C. George, Rapid
anastomosis of endothelial progenitor cell-derived vessels with host vasculature is
promoted by a high density of cotransplanted fibroblasts, Tissue Eng Part A 16(2) (2010)
585-94.
[57] M. Olausson, V.K. Kuna, G. Travnikova, H. Backdahl, P.B. Patil, R. Saalman, H.
Borg, A. Jeppsson, S. Sumitran-Holgersson, In Vivo Application of Tissue-Engineered
Veins Using Autologous Peripheral Whole Blood: A Proof of Concept Study,
EBioMedicine 1(1) (2014) 72-9.
[58] J.D. Roh, R. Sawh-Martinez, M.P. Brennan, S.M. Jay, L. Devine, D.A. Rao, T. Yi,
T.L. Mirensky, A. Nalbandian, B. Udelsman, N. Hibino, T. Shinoka, W.M. Saltzman, E.
Snyder, T.R. Kyriakides, J.S. Pober, C.K. Breuer, Tissue-engineered vascular grafts
transform into mature blood vessels via an inflammation-mediated process of vascular
remodeling, Proc Natl Acad Sci U S A 107(10) (2010) 4669-74.
[59] T.F. Whayne, A review of the role of anticoagulation in the treatment of peripheral
arterial disease, Int J Angiol 21(4) (2012) 187-94.
[60] Y. Wang, J. Hu, J. Jiao, Z. Liu, Z. Zhou, C. Zhao, L.J. Chang, Y.E. Chen, P.X. Ma,
B. Yang, Engineering vascular tissue with functional smooth muscle cells derived from
human iPS cells and nanofibrous scaffolds, Biomaterials 35(32) (2014) 8960-9.
[61] V.K. Bajpai, S.T. Andreadis, Stem cell sources for vascular tissue engineering and
regeneration, Tissue Eng Part B Rev 18(5) (2012) 405-25.

77
[62] P. Au, J. Tam, D. Fukumura, R.K. Jain, Bone marrow-derived mesenchymal stem
cells facilitate engineering of long-lasting functional vasculature, Blood 111(9) (2008)
4551-8.
[63] N.F. Huang, S. Li, Mesenchymal stem cells for vascular regeneration, Regen Med
3(6) (2008) 877-92.
[64] C.A. Herberts, M.S. Kwa, H.P. Hermsen, Risk factors in the development of stem cell
therapy, J Transl Med 9 (2011) 29.
[65] C. Xie, R.P. Ritchie, H. Huang, J. Zhang, Y.E. Chen, Smooth muscle cell
differentiation in vitro: models and underlying molecular mechanisms, Arterioscler
Thromb Vasc Biol 31(7) (2011) 1485-94.
[66] Z. Gong, L.E. Niklason, Use of human mesenchymal stem cells as alternative source
of smooth muscle cells in vessel engineering, Methods Mol Biol 698 (2011) 279-94.
[67] S. Sundaram, L.E. Niklason, Smooth muscle and other cell sources for human blood
vessel engineering, Cells Tissues Organs 195(1-2) (2012) 15-25.
[68] P.S. McFetridge, K. Abe, M. Horrocks, J.B. Chaudhuri, Vascular tissue engineering:
bioreactor design considerations for extended culture of primary human vascular smooth
muscle cells, ASAIO J 53(5) (2007) 623-30.
[69] E.S. Place, N.D. Evans, M.M. Stevens, Complexity in biomaterials for tissue
engineering, Nat Mater 8(6) (2009) 457-70.
[70] J.P. Stegemann, S.N. Kaszuba, S.L. Rowe, Review: advances in vascular tissue
engineering using protein-based biomaterials, Tissue Eng 13(11) (2007) 2601-13.
[71] C.J. Dong, Y.G. Lv, Application of Collagen Scaffold in Tissue Engineering: Recent
Advances and New Perspectives, Polymers-Basel 8(2) (2016).
[72] X. Wang, W. Zhai, C. Wu, B. Ma, J. Zhang, H. Zhang, Z. Zhu, J. Chang, Procyanidinscrosslinked aortic elastin scaffolds with distinctive anti-calcification and biological
properties, Acta Biomater 16 (2015) 81-93.
[73] S.L.M. Dahl, J.L. Blum, L.E. Niklason, Bioengineered Vascular Grafts: Can We Make
Them Off-the-Shelf?, Trends Cardiovas Med 21(3) (2011) 83-89.
[74] S. Ravi, E.L. Chaikof, Biomaterials for vascular tissue engineering, Regen Med 5(1)
(2010) 107-20.
[75] K.A. Rocco, M.W. Maxfield, C.A. Best, E.W. Dean, C.K. Breuer, In vivo applications
of electrospun tissue-engineered vascular grafts: a review, Tissue Eng Part B Rev 20(6)
(2014) 628-40.

78
[76] T.J. Sill, H.A. von Recum, Electrospinning: applications in drug delivery and tissue
engineering, Biomaterials 29(13) (2008) 1989-2006.
[77] I.M. El-Sherbiny, M.H. Yacoub, Hydrogel scaffolds for tissue engineering: Progress
and challenges, Glob Cardiol Sci Pract 2013(3) (2013) 316-42.
[78] J. Zhu, R.E. Marchant, Design properties of hydrogel tissue-engineering scaffolds,
Expert Rev Med Devices 8(5) (2011) 607-26.
[79] J. Liu, H. Zheng, P.S. Poh, H.G. Machens, A.F. Schilling, Hydrogels for Engineering
of Perfusable Vascular Networks, Int J Mol Sci 16(7) (2015) 15997-6016.
[80] N. Annabi, J.W. Nichol, X. Zhong, C. Ji, S. Koshy, A. Khademhosseini, F. Dehghani,
Controlling the porosity and microarchitecture of hydrogels for tissue engineering, Tissue
Eng Part B Rev 16(4) (2010) 371-83.
[81] F. Intranuovo, R. Gristina, F. Brun, S. Mohammadi, G. Ceccone, E. Sardella, F. Rossi,
G. Tromba, P. Favia, Plasma Modification of PCL Porous Scaffolds Fabricated by SolventCasting/ParticulateLeaching for Tissue Engineering, Plasma Process Polym 11(2) (2014)
184-195.
[82] L. Song, Q. Zhou, P. Duan, P. Guo, D. Li, Y. Xu, S. Li, F. Luo, Z. Zhang, Successful
development of small diameter tissue-engineering vascular vessels by our novel integrally
designed pulsatile perfusion-based bioreactor, PLoS One 7(8) (2012) e42569.
[83] S.I. Jeong, J.H. Kwon, J.I. Lim, S.W. Cho, Y. Jung, W.J. Sung, S.H. Kim, Y.H. Kim,
Y.M. Lee, B.S. Kim, C.Y. Choi, S.J. Kim, Mechano-active tissue engineering of vascular
smooth muscle using pulsatile perfusion bioreactors and elastic PLCL scaffolds,
Biomaterials 26(12) (2005) 1405-11.
[84] I. Martin, D. Wendt, M. Heberer, The role of bioreactors in tissue engineering, Trends
Biotechnol 22(2) (2004) 80-6.
[85] S.I. Jeong, S.Y. Kim, S.K. Cho, M.S. Chong, K.S. Kim, H. Kim, S.B. Lee, Y.M. Lee,
Tissue-engineered vascular grafts composed of marine collagen and PLGA fibers using
pulsatile perfusion bioreactors, Biomaterials 28(6) (2007) 1115-22.
[86] M. Lovett, G. Eng, J.A. Kluge, C. Cannizzaro, G. Vunjak-Novakovic, D.L. Kaplan,
Tubular silk scaffolds for small diameter vascular grafts, Organogenesis 6(4) (2010) 21724.
[87] D.G. Seifu, A. Purnama, K. Mequanint, D. Mantovani, Small-diameter vascular tissue
engineering, Nat Rev Cardiol 10(7) (2013) 410-21.
[88] D. Pankajakshan, D.K. Agrawal, Scaffolds in tissue engineering of blood vessels, Can
J Physiol Pharmacol 88(9) (2010) 855-73.

79
[89] F. Loth, P.F. Fischer, H.S. Bassiouny, Blood flow in end-to-side anastomoses, Annu
Rev Fluid Mech 40 (2008) 367-393.
[90] A.G. Mikos, S.W. Herring, P. Ochareon, J. Elisseeff, H.H. Lu, R. Kandel, F.J. Schoen,
M. Toner, D. Mooney, A. Atala, M.E. Van Dyke, D. Kaplan, G. Vunjak-Novakovic,
Engineering complex tissues, Tissue Eng 12(12) (2006) 3307-39.
[91] A. Kurane, N. Vyavahare, In vivo vascular tissue engineering: influence of cytokine
and implant location on tissue specific cellular recruitment, J Tissue Eng Regen Med 3(4)
(2009) 280-9.
[92] K.W. Lee, D.B. Stolz, Y. Wang, Substantial expression of mature elastin in arterial
constructs, Proc Natl Acad Sci U S A 108(7) (2011) 2705-10.
[93] J.P. Stegemann, H. Hong, R.M. Nerem, Mechanical, biochemical, and extracellular
matrix effects on vascular smooth muscle cell phenotype, J Appl Physiol (1985) 98(6)
(2005) 2321-7.
[94] O. Benzakour, C. Kanthou, S.M. Kanse, M.F. Scully, V.V. Kakkar, D.N. Cooper,
Evidence for cultured human vascular smooth muscle cell heterogeneity: isolation of clonal
cells and study of their growth characteristics, Thromb Haemost 75(5) (1996) 854-8.
[95] D.E. Muylaert, J.O. Fledderus, C.V. Bouten, P.Y. Dankers, M.C. Verhaar, Combining
tissue repair and tissue engineering; bioactivating implantable cell-free vascular scaffolds,
Heart 100(23) (2014) 1825-30.
[96] S. Tara, H. Kurobe, M.W. Maxfield, K.A. Rocco, T. Yi, Y. Naito, C.K. Breuer, T.
Shinoka, Evaluation of remodeling process in small-diameter cell-free tissue-engineered
arterial graft, J Vasc Surg 62(3) (2015) 734-43.
[97] M.J. Zhang, Y. Zhou, L. Chen, Y.Q. Wang, X. Wang, Y. Pi, C.Y. Gao, J.C. Li, L.L.
Zhang, An overview of potential molecular mechanisms involved in VSMC phenotypic
modulation, Histochem Cell Biol 145(2) (2016) 119-30.
[98] M.G. Frid, B.V. Shekhonin, V.E. Koteliansky, M.A. Glukhova, Phenotypic changes
of human smooth muscle cells during development: late expression of heavy caldesmon
and calponin, Dev Biol 153(2) (1992) 185-93.
[99] S. Chang, S. Song, J. Lee, J. Yoon, J. Park, S. Choi, J.K. Park, K. Choi, C. Choi,
Phenotypic modulation of primary vascular smooth muscle cells by short-term culture on
micropatterned substrate, PLoS One 9(2) (2014) e88089.
[100] G. Wang, L. Jacquet, E. Karamariti, Q. Xu, Origin and differentiation of vascular
smooth muscle cells, J Physiol 593(14) (2015) 3013-30.
[101] J.A. Beamish, P. He, K. Kottke-Marchant, R.E. Marchant, Molecular regulation of
contractile smooth muscle cell phenotype: implications for vascular tissue engineering,
Tissue Eng Part B Rev 16(5) (2010) 467-91.

80
[102] N.F. Worth, B.E. Rolfe, J. Song, G.R. Campbell, Vascular smooth muscle cell
phenotypic modulation in culture is associated with reorganisation of contractile and
cytoskeletal proteins, Cell Motil Cytoskeleton 49(3) (2001) 130-45.
[103] E.M. Rzucidlo, K.A. Martin, R.J. Powell, Regulation of vascular smooth muscle cell
differentiation, J Vasc Surg 45 Suppl A (2007) A25-32.
[104] G.K. Owens, M.S. Kumar, B.R. Wamhoff, Molecular regulation of vascular smooth
muscle cell differentiation in development and disease, Physiol Rev 84(3) (2004) 767-801.
[105] S.S. Rensen, P.A. Doevendans, G.J. van Eys, Regulation and characteristics of
vascular smooth muscle cell phenotypic diversity, Neth Heart J 15(3) (2007) 100-8.
[106] S.R. Peyton, C.B. Raub, V.P. Keschrumrus, A.J. Putnam, The use of poly(ethylene
glycol) hydrogels to investigate the impact of ECM chemistry and mechanics on smooth
muscle cells, Biomaterials 27(28) (2006) 4881-93.
[107] S.B.H. Timraz, R. Rezgui, S.M. Boularaoui, J.C.M. Teo, Stiffness of Extracellular
Matrix Components Modulates the Phenotype of Human Smooth Muscle Cells in Vitro
and Allows for the Control of Properties of Engineered Tissues, Procedia Engineer 110
(2015) 29-36.
[108] S.R. Peyton, P.D. Kim, C.M. Ghajar, D. Seliktar, A.J. Putnam, The effects of matrix
stiffness and RhoA on the phenotypic plasticity of smooth muscle cells in a 3-D
biosynthetic hydrogel system, Biomaterials 29(17) (2008) 2597-607.
[109] R.J. Petrie, K.M. Yamada, At the leading edge of three-dimensional cell migration,
J Cell Sci 125(Pt 24) (2012) 5917-26.
[110] H. Hong, J.P. Stegemann, 2D and 3D collagen and fibrin biopolymers promote
specific ECM and integrin gene expression by vascular smooth muscle cells, J Biomater
Sci Polym Ed 19(10) (2008) 1279-93.
[111] S. Lin, M. Sandig, K. Mequanint, Three-dimensional topography of synthetic
scaffolds induces elastin synthesis by human coronary artery smooth muscle cells, Tissue
Eng Part A 17(11-12) (2011) 1561-71.
[112] M. Rhinn, P. Dolle, Retinoic acid signalling during development, Development
139(5) (2012) 843-58.
[113] J.M. Miano, B.C. Berk, Retinoids: versatile biological response modifiers of vascular
smooth muscle phenotype, Circ Res 87(5) (2000) 355-62.
[114] Y.R. Zhang, Y.Q. Zhao, J.F. Huang, Retinoid-binding proteins: similar protein
architectures bind similar ligands via completely different ways, PLoS One 7(5) (2012)
e36772.

81
[115] R.K. Kam, Y. Deng, Y. Chen, H. Zhao, Retinoic acid synthesis and functions in early
embryonic development, Cell Biosci 2(1) (2012) 11.
[116] D. Dong, S.E. Ruuska, D.J. Levinthal, N. Noy, Distinct roles for cellular retinoic
acid-binding proteins I and II in regulating signaling by retinoic acid, J Biol Chem 274(34)
(1999) 23695-8.
[117] P. Germain, P. Chambon, G. Eichele, R.M. Evans, M.A. Lazar, M. Leid, A.R. De
Lera, R. Lotan, D.J. Mangelsdorf, H. Gronemeyer, International Union of Pharmacology.
LX. Retinoic acid receptors, Pharmacol Rev 58(4) (2006) 712-25.
[118] P. Neuville, Z. Yan, A. Gidlof, M.S. Pepper, G.K. Hansson, G. Gabbiani, A. Sirsjo,
Retinoic acid regulates arterial smooth muscle cell proliferation and phenotypic features in
vivo and in vitro through an RARalpha-dependent signaling pathway, Arterioscler Thromb
Vasc Biol 19(6) (1999) 1430-6.
[119] D.I. Axel, A. Frigge, J. Dittmann, H. Runge, I. Spyridopoulos, R. Riessen, R.
Viebahn, K.R. Karsch, All-trans retinoic acid regulates proliferation, migration,
differentiation, and extracellular matrix turnover of human arterial smooth muscle cells,
Cardiovasc Res 49(4) (2001) 851-62.
[120] H. Ou, J. Haendeler, M.R. Aebly, L.A. Kelly, B.C. Cholewa, G. Koike, A. KwitekBlack, H.J. Jacob, B.C. Berk, J.M. Miano, Retinoic acid-induced tissue transglutaminase
and apoptosis in vascular smooth muscle cells, Circ Res 87(10) (2000) 881-7.
[121] B. Zheng, M. Han, J.K. Wen, Role of Kruppel-like factor 4 in phenotypic switching
and proliferation of vascular smooth muscle cells, IUBMB Life 62(2) (2010) 132-9.
[122] M.V. Autieri, Kruppel-like factor 4: transcriptional regulator of proliferation, or
inflammation, or differentiation, or all three?, Circ Res 102(12) (2008) 1455-7.
[123] C. Wang, M. Han, X.M. Zhao, J.K. Wen, Kruppel-like factor 4 is required for the
expression of vascular smooth muscle cell differentiation marker genes induced by alltrans retinoic acid, J Biochem 144(3) (2008) 313-21.
[124] H. Haller, C. Lindschau, P. Quass, A. Distler, F.C. Luft, Differentiation of vascular
smooth muscle cells and the regulation of protein kinase C-alpha, Circ Res 76(1) (1995)
21-9.
[125] K. Tran-Lundmark, P. Tannenberg, B.H. Rauch, J. Ekstrand, P.K. Tran, U. Hedin,
M.G. Kinsella, Perlecan Heparan Sulfate Is Required for the Inhibition of Smooth Muscle
Cell Proliferation by All-trans-Retinoic Acid, J Cell Physiol 230(2) (2015) 482-7.
[126] A. Orlandi, S. Pucci, A. Ciucci, F. Pichiorri, A. Ferlosio, L.G. Spagnoli, Modulation
of clusterin isoforms is associated with all-trans retinoic acid-induced proliferative arrest
and apoptosis of intimal smooth muscle cells, Arterioscler Thromb Vasc Biol 25(2) (2005)
348-53.

82
[127] S. Tajima, A. Hayashi, T. Suzuki, Elastin expression is up-regulated by retinoic acid
but not by retinol in chick embryonic skin fibroblasts, J Dermatol Sci 15(3) (1997) 166-72.
[128] J.T. Mao, J.G. Goldin, J. Dermand, G. Ibrahim, M.S. Brown, A. Emerick, M.F.
McNitt-Gray, D.W. Gjertson, F. Estrada, D.P. Tashkin, M.D. Roth, A pilot study of alltrans-retinoic acid for the treatment of human emphysema, Am J Respir Crit Care Med
165(5) (2002) 718-23.
[129] G.J. Fisher, J.J. Voorhees, Molecular mechanisms of retinoid actions in skin, FASEB
J 10(9) (1996) 1002-13.
[130] B. Liu, C.S. Harvey, S.E. McGowan, Retinoic acid increases elastin in neonatal rat
lung fibroblast cultures, Am J Physiol 265(5 Pt 1) (1993) L430-7.
[131] S. McGowan, S.K. Jackson, M. Jenkins-Moore, H.H. Dai, P. Chambon, J.M. Snyder,
Mice bearing deletions of retinoic acid receptors demonstrate reduced lung elastin and
alveolar numbers, Am J Respir Cell Mol Biol 23(2) (2000) 162-7.
[132] Y. Liu, H. Chen, D. Mu, D. Li, Y. Zhong, N. Jiang, Y. Zhang, M. Xia, Association
of Serum Retinoic Acid With Risk of Mortality in Patients With Coronary Artery Disease,
Circ Res 119(4) (2016) 557-63.
[133] A. Hayashi, T. Suzuki, S. Tajima, Modulations of elastin expression and cell
proliferation by retinoids in cultured vascular smooth muscle cells, J Biochem 117(1)
(1995) 132-6.
[134] L.M. Barone, B. Faris, S.D. Chipman, P. Toselli, B.W. Oakes, C. Franzblau,
Alteration of the extracellular matrix of smooth muscle cells by ascorbate treatment,
Biochim Biophys Acta 840(2) (1985) 245-54.
[135] M. Chojkier, K. Houglum, J. Solis-Herruzo, D.A. Brenner, Stimulation of collagen
gene expression by ascorbic acid in cultured human fibroblasts. A role for lipid
peroxidation?, J Biol Chem 264(28) (1989) 16957-62.
[136] H. Qiao, J. Bell, S. Juliao, L. Li, J.M. May, Ascorbic acid uptake and regulation of
type I collagen synthesis in cultured vascular smooth muscle cells, J Vasc Res 46(1) (2009)
15-24.
[137] J.M. Davidson, P.A. LuValle, O. Zoia, D. Quaglino, Jr., M. Giro, Ascorbate
differentially regulates elastin and collagen biosynthesis in vascular smooth muscle cells
and skin fibroblasts by pretranslational mechanisms, J Biol Chem 272(1) (1997) 345-52.
[138] B.M. Ogle, D.L. Mooradian, Manipulation of remodeling pathways to enhance the
mechanical properties of a tissue engineered blood vessel, J Biomech Eng 124(6) (2002)
724-33.

83
[139] S. Grenier, M. Sandig, K. Mequanint, Polyurethane biomaterials for fabricating 3D
porous scaffolds and supporting vascular cells, J Biomed Mater Res A 82(4) (2007) 8029.
[140] Z. Urban, O. Agapova, V. Hucthagowder, P. Yang, B.C. Starcher, M.R. Hernandez,
Population differences in elastin maturation in optic nerve head tissue and astrocytes,
Invest Ophthalmol Vis Sci 48(7) (2007) 3209-15.
[141] X. Wu, Y. Zou, Q. Zhou, L. Huang, H. Gong, A. Sun, K. Tateno, K. Katsube, F.
Radtke, J. Ge, T. Minamino, I. Komuro, Role of Jagged1 in arterial lesions after vascular
injury, Arterioscler Thromb Vasc Biol 31(9) (2011) 2000-6.
[142] X. Wang, T. Lou, W. Zhao, G. Song, C. Li, G. Cui, The effect of fiber size and pore
size on cell proliferation and infiltration in PLLA scaffolds on bone tissue engineering, J
Biomater Appl 30(10) (2016) 1545-51.
[143] L. Olah, K. Filipczak, Z. Jaegermann, T. Czigany, L. Borbas, S. Sosnowski, P.
Ulanski, J.M. Rosiak, Synthesis, structural and mechanical properties of porous polymeric
scaffolds for bone tissue regeneration based on neat poly(epsilon-caprolactone) calcium
carbonate, Polym Advan Technol 17(11-12) (2006) 889-897.
[144] M.A. Woodruff, D.W. Hutmacher, The return of a forgotten polymerPolycaprolactone in the 21st century, Prog Polym Sci 35(10) (2010) 1217-1256.
[145] B.D. Ulery, L.S. Nair, C.T. Laurencin, Biomedical Applications of Biodegradable
Polymers, J Polym Sci Pol Phys 49(12) (2011) 832-864.
[146] Y. Hong, J. Guan, K.L. Fujimoto, R. Hashizume, A.L. Pelinescu, W.R. Wagner,
Tailoring the degradation kinetics of poly(ester carbonate urethane)urea thermoplastic
elastomers for tissue engineering scaffolds, Biomaterials 31(15) (2010) 4249-58.
[147] Q. Jiang, H. Xu, S. Cai, Y. Yang, Ultrafine fibrous gelatin scaffolds with deep cell
infiltration mimicking 3D ECMs for soft tissue repair, J Mater Sci Mater Med 25(7) (2014)
1789-800.
[148] M.T. Nelson, L. Pattanaik, M. Allen, M. Gerbich, K. Hux, J.J. Lannutti,
Recrystallization improves the mechanical properties of sintered electrospun
polycaprolactone, J Mech Behav Biomed Mater 30 (2014) 150-8.
[149] S. Lin, K. Mequanint, The role of Ras-ERK-IL-1beta signaling pathway in
upregulation of elastin expression by human coronary artery smooth muscle cells cultured
in 3D scaffolds, Biomaterials 33(29) (2012) 7047-56.
[150] P.J. Woodward, D.H. Merino, B.W. Greenland, I.W. Hamley, Z. Light, A.T. Slark,
W. Hayes, Hydrogen Bonded Supramolecular Elastomers: Correlating Hydrogen Bonding
Strength with Morphology and Rheology, Macromolecules 43(5) (2010) 2512-2517.

84
[151] Z. Tosun, P.S. McFetridge, Improved recellularization of ex vivo vascular scaffolds
using directed transport gradients to modulate ECM remodeling, Biotechnol Bioeng 110(7)
(2013) 2035-2045.
[152] P. Losi, S. Lombardi, E. Briganti, G. Soldani, Luminal surface microgeometry affects
platelet adhesion in small-diameter synthetic grafts, Biomaterials 25(18) (2004) 4447-55.
[153] Z.G. Tang, R.A. Black, J.M. Curran, J.A. Hunt, N.P. Rhodes, D.F. Williams, Surface
properties and biocompatibility of solvent-cast poly[-caprolactone] films, Biomaterials
25(19) (2004) 4741-8.
[154] B.H. Kim, D.H. Lee, J.Y. Kim, D.O. Shin, H.Y. Jeong, S. Hong, J.M. Yun, C.M.
Koo, H. Lee, S.O. Kim, Mussel-inspired block copolymer lithography for low surface
energy materials of teflon, graphene, and gold, Adv Mater 23(47) (2011) 5618-22.
[155] M. Choudhury, S. Mohanty, S. Nayak, Effect of Different Solvents in Solvent
Casting of Porous PLA Scaffolds-In Biomedical and Tissue Engineering Applications, J
Biomater Tiss Eng 5(1) (2015) 1-9.
[156] S. Bertoldi, S. Fare, M.C. Tanzi, Assessment of scaffold porosity: the new route of
micro-CT, J Appl Biomater Biomech 9(3) (2011) 165-75.
[157] G. Lalwani, A. Gopalan, M. D'Agati, J.S. Sankaran, S. Judex, Y.X. Qin, B.
Sitharaman, Porous three-dimensional carbon nanotube scaffolds for tissue engineering, J
Biomed Mater Res A 103(10) (2015) 3212-25.
[158] S. Grenier, M. Sandig, D.W. Holdsworth, K. Mequanint, Interactions of coronary
artery smooth muscle cells with 3D porous polyurethane scaffolds, J Biomed Mater Res A
89(2) (2009) 293-303.
[159] H.Y. Oh, X. Jin, J.G. Kim, M.J. Oh, X. Pian, J.M. Kim, M.S. Yoon, C.I. Son, Y.S.
Lee, K.C. Hong, H. Kim, Y.J. Choi, K.Y. Whang, Characteristics of primary and
immortalized fibroblast cells derived from the miniature and domestic pigs, BMC Cell Biol
8 (2007) 20.
[160] J.P. Mazzoccoli, D.L. Feke, H. Baskaran, P.N. Pintauro, Mechanical and cell
viability properties of crosslinked low- and high-molecular weight poly(ethylene glycol)
diacrylate blends, J Biomed Mater Res A 93(2) (2010) 558-66.
[161] G.D. Nicodemus, S.J. Bryant, Cell encapsulation in biodegradable hydrogels for
tissue engineering applications, Tissue Eng Part B Rev 14(2) (2008) 149-65.
[162] T. Hodgkinson, X.F. Yuan, A. Bayat, Electrospun silk fibroin fiber diameter
influences in vitro dermal fibroblast behavior and promotes healing of ex vivo wound
models, J Tissue Eng 5 (2014) 2041731414551661.

85
[163] V.M. Quent, D. Loessner, T. Friis, J.C. Reichert, D.W. Hutmacher, Discrepancies
between metabolic activity and DNA content as tool to assess cell proliferation in cancer
research, J Cell Mol Med 14(4) (2010) 1003-13.
[164] S. Patel, Y. Shi, R. Niculescu, E.H. Chung, J.L. Martin, A. Zalewski, Characteristics
of coronary smooth muscle cells and adventitial fibroblasts, Circulation 101(5) (2000) 52432.
[165] A. Bhattacharyya, S. Lin, M. Sandig, K. Mequanint, Regulation of vascular smooth
muscle cell phenotype in three-dimensional coculture system by Jagged1-selective Notch3
signaling, Tissue Eng Part A 20(7-8) (2014) 1175-87.
[166] S. Grenier, M. Sandig, K. Mequanint, Smooth muscle alpha-actin and calponin
expression and extracellular matrix production of human coronary artery smooth muscle
cells in 3D scaffolds, Tissue Eng Part A 15(10) (2009) 3001-11.
[167] T. Steynberg, M. Visagie, T. Mqoco, A. Idicula, S. Moolman, W. Richter, A. Joubert,
Qualitative assessment of smooth muscle cells propagated on 2D-and 3D-polycaprolactone
polymers via scanning electron microscope., Biomed Res-India 23(2) (2012) 191-198.
[168] R. Pankov, K.M. Yamada, Fibronectin at a glance, J Cell Sci 115(Pt 20) (2002) 38613.
[169] G. Dubey, K. Mequanint, Conjugation of fibronectin onto three-dimensional porous
scaffolds for vascular tissue engineering applications, Acta Biomater 7(3) (2011) 1114-25.
[170] A. Tiwari, A. Kidane, H. Salacinski, G. Punshon, G. Hamilton, A.M. Seifalian,
Improving endothelial cell retention for single stage seeding of prosthetic grafts: use of
polymer sequences of arginine-glycine-aspartate, Eur J Vasc Endovasc Surg 25(4) (2003)
325-9.
[171] G.A. Villalona, B. Udelsman, D.R. Duncan, E. McGillicuddy, R.F. Sawh-Martinez,
N. Hibino, C. Painter, T. Mirensky, B. Erickson, T. Shinoka, C.K. Breuer, Cell-seeding
techniques in vascular tissue engineering, Tissue Eng Part B Rev 16(3) (2010) 341-50.
[172] M.M. Medhora, Retinoic acid upregulates beta(1)-integrin in vascular smooth
muscle cells and alters adhesion to fibronectin, Am J Physiol Heart Circ Physiol 279(1)
(2000) H382-7.
[173] W.Y. Hu, N. Fukuda, C. Satoh, T. Jian, A. Kubo, M. Nakayama, H. Kishioka, K.
Kanmatsuse, Phenotypic modulation by fibronectin enhances the angiotensin II-generating
system in cultured vascular smooth muscle cells, Arterioscler Thromb Vasc Biol 20(6)
(2000) 1500-5.
[174] L. Ades, A. Guerci, E. Raffoux, M. Sanz, P. Chevallier, S. Lapusan, C. Recher, X.
Thomas, C. Rayon, S. Castaigne, O. Tournilhac, S. de Botton, N. Ifrah, J.Y. Cahn, E.
Solary, C. Gardin, N. Fegeux, D. Bordessoule, A. Ferrant, S. Meyer-Monard, N. Vey, H.
Dombret, L. Degos, S. Chevret, P. Fenaux, Very long-term outcome of acute

86
promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the
European APL Group experience, Blood 115(9) (2010) 1690-6.
[175] S. Wakino, U. Kintscher, S. Kim, S. Jackson, F. Yin, S. Nagpal, R.A. Chandraratna,
W.A. Hsueh, R.E. Law, Retinoids inhibit proliferation of human coronary smooth muscle
cells by modulating cell cycle regulators, Arterioscler Thromb Vasc Biol 21(5) (2001) 74651.
[176] A.J. Michels, B. Frei, Myths, artifacts, and fatal flaws: identifying limitations and
opportunities in vitamin C research, Nutrients 5(12) (2013) 5161-92.
[177] C.M. Shanahan, P.L. Weissberg, Smooth muscle cell heterogeneity: patterns of gene
expression in vascular smooth muscle cells in vitro and in vivo, Arterioscler Thromb Vasc
Biol 18(3) (1998) 333-8.
[178] A.J. Ryan, F.J. O'Brien, Insoluble elastin reduces collagen scaffold stiffness,
improves viscoelastic properties, and induces a contractile phenotype in smooth muscle
cells, Biomaterials 73 (2015) 296-307.

87

Appendix: Copyright Permission
Copyright Permissions for Figures that appeared in Chapter 2.

Figure 2.1
Obtained from Oxford University Press.

Figure 2.5
Obtained from Wolters Kluwer Health, Inc.

88

Curriculum Vitae
Brandon Chaffay

Education
2015-Present

MB BCh BAO Candidate
University College Dublin School of Medicine, Ireland

2013-2016

MESc. Chemical and Biochemical Engineering
Western University, London, ON, Canada

2009-2013

B.Sc. Life Sciences ssp. Microbiology & Immunology
Queen’s University, Kingston, ON, Canada

Related Work Experience
2014-2015

Graduate Teaching Assistant
Department of Chemical and Biochemical Engineering
Western University, London, ON, Canada

